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Abstract 
TRIM24 AS AN ONCOGENE IN THE MAMMARY GLAND 
 
Aundrietta DeVan Duncan, M.S. 
 
Advisory Professor: Michelle C. Barton 
 
 
Despite the many advances made in breast cancer research and treatments, breast cancer remains 
one of the deadliest diseases plaguing women worldwide.  While many findings on genetic 
mutations and their role in predisposing people to breast cancer have been uncovered, we are just 
beginning to understand the extent to which epigenetic regulators promote tumorigenic 
phenotypes, metastasis, and chemotherapeutic resistance.  Moreover, new experimental tools 
offer the ability to address questions we were previously unable to assess.   My project takes 
advantage of a new mouse model to understand the role of a proto-oncogenic, transcriptional co-
regulator, TRIM24, in mammary gland development and disease. 
We previously reported an unknown binding partner and negative regulator of p53, 
Tripartite Motif protein 24 (TRIM24). TRIM24 is a multifunctional protein, which acts as a co-
regulator of estrogen receptor, a histone reader with tandem PHD and Bromo domains, and a 
ubiquitin E3-ligase targeting p53 by its RING domain. TRIM24 is over-expressed in human breast 
cancers, which is correlated with poor patient survival. Previous in cellulo studies in our lab show 
that TRIM24 over-expression leads to transformation of immortalized human mammary epithelial 
cells. However, whether over-expression of TRIM24 drives cancer development in vivo remains 
unknown.  To address this gap in our knowledge, we developed a physiologically relevant mouse 
model to determine if over-expression of TRIM24 promotes tumor development in mammary 
 viii 
epithelial cells, consistent with TRIM24 function as an oncogene.  We hypothesize that TRIM24 
acts as an oncogene in the mammary gland.  
To test this hypothesis, we generated transgenic mice, which in the presence of cre-
recombinase, conditionally over-express mouse TRIM24 fused to a C-terminal FLAG epitope tag. 
Our studies reveal that increased expression of Trim24 in the mouse mammary gland is sufficient 
to drive tumorigenesis by 8 months of age. To facilitate genome wide and targeted therapeutic 
studies, I developed multiple primary cell lines (tumor and normal mammary epithelia) from each 
genotype.  Colony formation and proliferation assays indicate that over-expression of TRIM24 gives 
cells a survival and proliferative advantage. RNA-deep sequencing and genome-wide binding 
profiles of these tumor-derived cell lines reveal that TRIM24 over-expression may be a direct driver 
of the epithelial-mesenchymal transition (EMT). These data corroborate unpublished in cellulo 
data from our lab, which implicate TRIM24 as a metastasis-promoting protein through its ability to 
activate EMT gene expression. Furthermore, we have observed an over-representation of 
metaplastic breast carcinomas (MpBC), a rare and devastatingly aggressive disease that has an 
EMT signature, in profiles of tumors generated in our mouse model. We have performed exome-
sequencing, RNA-sequencing and immunohistochemistry on mice, which are currently being 
compared to human MpBC patient samples with the end goal of identifying the common 
alterations and substantiate TRIM24 as a player in the development of the MpBC phenotype.  
Finally, we present our mouse model as a useful tool to test the efficacy of potential therapeutics 
targeting MpBC and other breast cancers. 
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Chapter 1: INTRODUCTION  
The evolution of the mammary gland, the defining organ of an entire class of animals, has been 
hypothesized to have developed not only for nutritional purposes and establishment of 
neonatal immunological competence [1]. The development and healthy maintenance of this 
life sustaining structure are complex. This tissue, being mitotically active during most of a 
woman’s childbearing years, is constantly undergoing structural modifications, being put at 
risk for proliferation-related diseases including hyperplasia and cancer. In fact, breast cancer 
is still amongst the most highly diagnosed cancer in women in the United States today, 
accounting for 30% of new cancer diagnoses and 14% of cancer deaths [2]. Fortunately, studies 
to delineate the developmental and disease pathways of the mammary gland have led to some 
remarkable breakthroughs for patients in terms of life saving detection and treatment options 
for several types of breast cancers. Still there remain many women who develop and succumb 
to the most aggressive and deadly forms of this disease. For these women, advances and 
discoveries, leading to earlier diagnosis and targeted therapeutic opportunities, are 
desperately needed to increase hope for survival.   
 
 2 
1.1 Comparative Anatomy of the Mammary Gland 
The differences in breast manifestation: size, shape, number, location, between the many 
species of mammals on earth are remarkable. However, there are significant similarities 
between the development of the basic structural unit or mammary gland between species, 
especially rodents and humans, that make mice suitable models for studying common 
mechanisms of development and disease progression[3]. The human breast, or mammary 
gland, is comprised mostly of adipose and connective tissues, this cellular compartment is 
termed the stroma.  The main functional, milk-secreting structure of the breast is the glandular 
epithelium, which is organized in a ductal structure. In humans, these ducts form clusters, 
commonly referred to as the Terminal Duct Lobular Unit (TDLU), which differentiate further 
during pregnancy in preparation for lactation [4].  While the mouse mammary ductal system 
extends through the entirety of the fat pad, it does not have differentiated lobules.  However, 
the mouse mammary gland undergoes extensive proliferation and differentiation in response 
to secreted pregnancy-associated hormones, which in turn give rise to lobules that will later 
secrete milk (Figure 1). 
According to the “One-half Rule”, most mammals generally possess half the number of 
mammary glands as their average litter size and approximately the same number of mammary 
glands as their maximum litter size[5].   With an average litter size of one, humans have one 
pair of mammary glands while mice having an average litter size of five have five pairs of 
mammary fat pads located between the skin and the peritoneum, each containing a network 
of glands which ultimately secrete and deliver milk to nursing young through external 
nipples[4]. 
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Similar to the mouse, human mammary glands develop only to a rudimentary ductal branch 
during embryogenesis, while the remaining development occurs at the initiation of puberty 
and continues throughout the lifetime of the organism. The mammary gland has two major 
cell types, luminal epithelial cells which secrete milk into the lumen to be delivered to nursing 
young, and myoepithelial cells which are responsible for contracting the glands during 
lactation, additionally there are the basement lamina, fibroblasts, adipose and connective 
tissue. Complex inter-cellular coordination of hormones, growth factors, and cytokines, is 
essential to the maintenance of the mammary gland. During murine embryonic development, 
between embryonic days 10 and 15, mammary buds form along the milk lines and proliferation 
is temporarily halted until hormonal signaling begins [6, 7]. At this time, terminal end buds 
(TEBs) are first observed. TEBs are uniquely equipped to give rise to the mammary gland, as 
the TEB structure contains body cells, destined to become epithelial cells, and cap cells, which 
develop into myoepithelial cells, in the mature mammary gland. Beginning at 4 weeks of age 
in mice and around 10 years of age in humans, hormone secretion from the ovaries stimulates 
ligand-dependent nuclear receptor target gene transcription, leading to the reactivation of 
mammary gland development [4]. 
 Though there is considerable anatomical diversity between species, postnatal development 
of the mammary gland in response to hormone signaling is common to all mammals. This 
conservation has been advantageous and exploited by researchers to uncover the mechanisms 
governing the development of the mammary gland.  
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Figure 1 | Comparative anatomy of the mammary gland. Illustration of the nulliparous (non-
pregnant) and pregnant mammary glands of the human and mouse. Modified with permission 
from Carroll, J. et al. Nat. Rev. Cancer 2016.[8] License number 4147840467959. 
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1.2 Transcriptional Regulation in the Developing Mammary Gland 
 The phenomenon that allows the millions of cells with identical genetic information to 
differentiate into distinct cell types that give rise to a multicellular organism is governed by 
epigenetics [9]. The sensing of environmental cues ultimately results in chromatin remodeling 
by altering nucleosome-associated, post-translational modifications (PTMs) of histones, by 
mobilizing nucleosomes to change chromatin structure accessibility or both.  Overall, 
chromatin remodeling facilitates subsequent induction or repression of gene expression that 
comprise epigenetic programs of gene regulation [10].  These mechanisms are functioning in 
the developing mammary gland, mediated by hormonal signaling through the nuclear 
receptors and their co-regulators. 
The initial hormone to be released from the ovary at puberty is 17ß-estradiol, commonly 
termed estrogen or E2, stimulating estrogen receptor-alpha (ER) target gene-mediated 
ductal elongation.  Once the ductal branches have acquired their maximum length by reaching 
the end of the mammary fat pad, the cells in the terminal end bud exit mitosis and the TEB 
decreases in size [11]. Side branching is mediated by progesterone (P4)-bound progesterone 
receptor (PR). While approximately 30% of luminal epithelial cells express ER and PR, it is 
primarily those cells lacking the hormone receptors that are responsible for the proliferative 
activity that populate the mammary gland, suggesting that the response to systemic estrogen 
is paracrine in nature [12] [8].  ER null mice are infertile and lack properly developed 
mammary glands, while PR null mice demonstrate significant impairment in the development 
of all reproductive organs including the mammary gland [13]. Prolactin (Prl) induced 
transcription is essential for epithelial cells to differentiate into alveoli which produce milk 
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during pregnancy [14] (Figure 2). ER, PR, and Prl synchronize with growth hormones and co-
regulatory proteins to achieve their full transcriptional effect, acting on chromatin structure to 
regulate gene expression. [15]   
Transcriptional co-regulators, whether activators or repressors, are key factors in enhancing 
the transcriptional outcomes of nuclear receptor proteins. A large number of transcriptional 
co-regulators and general regulators of chromatin structure also known as ‘epigenetic 
regulators’ or ‘chromatin modifiers’ have been identified that modulate in some way, ligand-
dependent nuclear receptor signaling. 
The best understood of these co-regulatory relationships and their contribution to 
homeostasis and development is that of ER with its numerous nuclear receptor transcriptional 
co-regulators (co-activators or co-repressors) [16].  For example, SRC-3, a transcriptional co-
activator of ER, is one of many molecules that play a role in proper maintenance of the 
mammary gland by coordinating chromatin remodeling, histone acetylation, and splicing 
through interactions with various protein complexes [17] (Figure 3). When SRC-3 is aberrantly 
expressed, dysfunction of SRC-3-regulated activities causes mammary tumorigenesis.  With 
the complex web of proteins involved in the ongoing reconstruction of the mammary gland, it 
is reasonable to imagine that inappropriate activation of any nuclear receptor or co-activator 
could mean disaster for the continued health of the organ, resulting in disease.  
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Figure 2 | Mammary Gland Development. Diagram of the stages of mammary gland 
development and the major hormone receptors active at each stage. Modified with permission 
form Inman et al. Development 2015. [18] 
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Figure 3 | Nuclear Receptor Epigenetics. Illustration of the network of proteins SRC interacts 
with to regulate nuclear receptor target gene transcription. Reprinted with permission from 
Brisken et al. CSHLPB 2010. [17] 
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1.3 Pathologies of the breast with a focus on metaplastic breast cancers 
The most recent World Health Organization Classification of Tumors (2012) describes 31 
pathologically distinct tumors of the breast [19].  There are currently 5 recognized breast 
tumor subtypes, defined by molecular characteristics – Normal-like, Luminal A, Luminal B, 
Triple negative (basal like), and HER2-type [20]. Categorizing the inter-tumoral heterogeneity 
that exists between breast tumors offers focused diagnostics that ultimately guide treatment; 
however, intra-tumoral heterogeneity leads to challenges both in diagnosis and in determining 
the appropriate therapy for patients [21]. Of the molecular subtypes, Triple Negative breast 
cancers (TNBC’s) are negative for Estrogen Receptor, Progesterone Receptor and do not over-
express HER2 and have the worst outcome for patients, as they are the most aggressive and 
least responsive to therapy [22]. With no current, targeted therapeutic options available for 
TNBC, greater efforts are needed to understand the molecular underpinnings of TNBC’s.  
 To that end, seven subgroups of TNBC have been defined based on clustering of 
molecular characteristics. The subtypes are as follows: basal-like 1/2, mesenchymal and 
mesenchymal stem-like, luminal androgen receptor, immunomodulatory, and HER2 enriched 
[23].   These new subtypes are clustered based on commonly altered molecular pathways and 
potential therapeutic targets. As suggested by their name, the mesenchymal subtype of 
tumors express markers of epithelial-mesenchymal transition (EMT).  Within the mesenchymal 
subtype of TNBCs is a particularly aggressive tumor type, metaplastic breast cancer (MpBC), a 
rare breast cancer subtype comprising 0.5-1% of total diagnosed breast cancers. MpBC is 
diagnosed solely by histological features of tumor malignant cells that stain positive for both 
epithelial and mesenchymal characteristics. A study revealed that diagnoses of MBC increased 
 10 
dramatically between 1980 and 2008 [24].  These data show that 80% of MpBC cases were 
diagnosed after 2000, which may be due to previous misclassification of the cases, wider 
acceptance of MpBC as a distinct subtype or a true increase in incidence. Histological studies 
revealed that MpBCs are positive for a broad range of cytokeratins, frequently expressing 
myoepithelial markers and commonly negative for hormone receptors [25], and recent 
genomic profiling led to classification of MpBCs as a subtype of TNBC [23, 26, 27]. In the clinic, 
women with MpBC present with high-grade disease, are typically refractory to treatment and 
have a high incidence of recurrence [24]. Within the tumors that are classified as metaplastic, 
there are yet more subtypes defined by histology and molecular features. Those classifications 
are: metaplastic carcinoma of no special type, low-grade adenosquamous carcinoma, 
fibromatosis-like metaplastic carcinoma, spindle cell carcinoma, squamous cell carcinoma, 
chondroid differentiated, osseous differentiated, other types of differentiated, mixed 
metaplastic carcinoma, and myoepithelial carcinoma [19, 28, 29]. 
The World health organization defines metaplastic carcinomas as: 
“[…] a general term referring to a heterogeneous group of neoplasms generally characterized 
by an intimate admixture of adenocarcinoma with dominant areas of spindle cell, squamous, 
and/or mesenchymal differentiation[…]”  [19] 
As defined by the National Cancer Institute, metaplasia is the change of cells to a form that 
does not normally occur in the tissue in which it is found.  This type of change is characteristic 
to MpBC, the origin of which is still debated. The theory most widely supported is that 
epithelial cells of the breast undergo biochemical changes causing them to express diagnostic 
markers, physically resemble and function more like mesenchymal cells [26]. This process is 
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generally known as the epithelial-to-mesenchymal transition or EMT] [30]. During 
embryogenesis, the process of EMT is required in order for epithelial cells of the epiblast to 
take on the characteristics of mesenchymal cells and form the primitive streak, ultimately 
giving rise to each germ layer and every cell in an organism. Numerous studies have identified 
the untimely reactivation of EMT-associated transcription factors in association with tumor 
progression and metastasis [31]. Moreover, the upregulation of EMT-associated protein is 
generally correlated with increased aggressiveness of tumors and poor survival of patients.  
Such proteins, who’s useful developmental functions are hijacked in tumor cells, granting 
proliferative and survival advantages are referred to as proto-oncogenes.  
 The most well studied oncogenes in breast cancer are ErbB2 and PI3KCA both of which 
are used in the clinic as diagnostic indicators of tumor type and are exploited as therapeutic 
targets. While identification of these two genes are beneficial for segregating patients for 
therapy, they only represent a subset of breast cancers. In order to impact those patients from 
whom no targeted therapy exists, we must first identify other potential proto-oncogenes. Key 
identifiers of oncogenes are proteins that are expressed at high levels in cancer and give cells 
proliferative and survival advantages through their ability to coordinate a malignant program 
in cells. Our lab discovered a potential oncogene in breast cancer, Tripartite Motif Family 
Member 24 (TRIM24) [32].  This thesis is focused on the studies I have performed to show in 
vivo that aberrant over expression of TRIM24 in mammary epithelial cells is sufficient for 
mammary tumorigenesis and, thus, to define TRIM24 as an oncogene. 
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1. 4 TRIM24   
TRIM24 (TIF1) was originally identified as a B-raf fusion protein and mediator of ligand 
dependent transcriptional activation of Retinoid X Receptor and Retinoic Acid Receptor [33]. 
TRIM24 is a multifunctional protein with 5 unique protein domains.  The C3HC4-zinc finger 
Really Interesting New Gene (RING) domain, set of B-boxes, and Coiled-coil domain are the 
defining domains of the RBCC family of over 70 proteins [34, 35]. Its tandem Plant 
Homeodomain (PHD) and Bromodomains set TRIM24 as the founding member of the 
Transcription Intermediary Factor (TIF1) sub-family of TRIM proteins, which includes 
structurally similar hetero-dimerizing partners TRIM28 (TIF1) and TRIM33 (TIF1) [35]. 
Between the coiled-coil domain and the PHD domain is a 435 amino acid linker region, which 
houses a LXXLL (L: leucine, X:any amino acid) consensus nuclear receptor interaction motif 
[Heery 1997](aa 760-765) through which it interacts with ER[36].   
The Barton Lab first discovered TRIM24 as a RING-dependent E3-ubiquitin ligase, of p53 
through a mass spectrometry analysis of endogenous p53 isolated from mouse embryonic 
stem cells after DNA damage [37]. TRIM24 forms polyubiquitin chains on p53 resulting in p53 
being targeted to the proteasome for degradation. Additionally, DNA damage that activates 
ATM kinase in turn activates p53 and represses TRIM24 activity by site-specific 
phosphorylation, establishing an auto-regulatory feedback loop between p53 as an activator 
of TRIM24 transcription and TRIM24 as a negative regulator of p53 that terminates DNA 
damage response [38]. TRIM24 interacts with nuclear receptors, including Retinoic Acid 
Receptor [39] Androgen Receptor [40], and Estrogen Receptor [32], through the LXXLL 
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sequence motif in the linker region to function as a ligand-dependent transcriptional co-
regulator. At the C-terminus, a tandem PHD-Bromodomain acts as a combinatorial epigenetic 
reader, employing a single surface of the PHD-Bromodomain to interact with acetylated lysines 
23 on the N-terminus tail of histone H3 (H3K23ac) and unmodified lysine 4 on the same histone 
tail (H3K4me0). This “histone reader” function of TRIM24 mediates recognition of specifically 
modified chromatin, associated with gene regulation. As we previously showed in ER-positive, 
breast cancer-derived MCF7 cells, TRIM24-dependent recruitment of ligand-bound ER to 
EREs in response to estrogen treatment led to increased transcription of ERtarget genes, 
including PGR and GREB1 [32].  
 
 
 
 
 
 
Figure 4 | Illustration of TRIM24 and its domains with functions listed.  
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1.5 TRIM4 as an oncogene 
Recent reports correlated aberrantly high TRIM24 expression with poor patient prognosis, 
poor differentiation, advanced stage, chemo-resistance and recurrence in a wide range of 
cancer types [41-47]. These studies offer a strong correlative, but not a causative, role for 
TRIM24 over-expression in tumorigenesis.  The Barton lab set out to determine the functional 
consequences of aberrant expression of TRIM24 and assess cause-and-effect in cellular 
transformation. In immortalized human mammary epithelial cells (iHMECs), which express low 
levels of TRIM24 and are not transformed, ectopic expression of TRIM24 led to transformation.  
These transformed cells readily grow in soft agar and as xenograft tumors, concomitant with 
disrupted transcriptional regulation of key metabolic regulatory genes and increased glucose 
metabolism [48]. These studies demonstrate that TRIM24 is oncogenic in vitro; however, 
whether TRIM24 is an oncogene in vivo remained unknown. 
 
Hypothesis and aims of the work  
Taking into account the mounting, correlative evidence across a broad spectrum of human 
tumors for TRIM24’s potential role as an oncogene, in addition to our lab’s in vitro studies, I 
hypothesize that TRIM24 functions as an oncogene in the mammary gland and has the capacity 
to drive tumorigenesis in vivo. The aims of this study are, a) to determine if over-expression of 
TRIM24 in the mammary luminal epithelium is sufficient to drive tumor development in vivo 
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and b) to determine the tissue-specific, transcription co-regulatory functions of TRIM24 by 
identifying TRIM24-induced transcriptional programs in developing mammary gland in vivo. 
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CHAPTER 2: MATERIALS AND METHODS  
2.1 Mice 
Trim24-/- mice [49], generated by the deletion of mTRIM24 exon 1, were previously available 
in the laboratory.  FVB wild type, Trp53-/- (129), and MMTV-CreTg/Tg mice were obtained from 
the Jackson Laboratory. 
Generation of the Flag-TRIM24 transgenic mouse. (Resources previously available in the 
laboratory, in collaboration with the Behringer laboratory, MD Anderson Cancer Center) 
 The pBac-UbC-LoxStop-Trim24 vector was constructed to insert exogenous Flag-tagged 
mouse Trim24 cDNA into the mouse genome by way of random single copy integration carried 
out by the PiggyBac transposase. Mouse Trim24 cDNA was cloned from the Pyx-Asc-Trim24 
plasmid into the pENTR/D-TOPO (Invitrogen) plasmid resulting in the pENTR/D-mTRIM24-FL-
3XFlag plasmid. The mTRIM24-FL-3xFlag fragment was transferred into the destination vector, 
pCoE2loxGW (Invitrogen) by LR clonase; plasmids were confirmed by sequencing. The 
PiggyBac transposase mRNA was synthesized and purified in vitro from pCMV-mPB plasmid 
the EnoFree Plasmid Kit (Qiagen).  PiggyBac mRNA and pCoE2loxGW-mTRIM24-3xFlag were 
injected to pronuclei of FVB mice. Transgene positive progeny were confirmed by LacZ staining 
and PCR genotyping using the primer pairs p23 and p24 (Appendix 1).    
 
2.2 Southern blot analysis of Trim24 genotypes  
Southern blotting was used to confirm presence of the transgene in mice staining positively 
for LacZ. A total of 10ug genomic DNA, isolated from mouse tails, was digested with the 
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restriction enzyme NdeI and resolved by electrophoresis on a 1% agarose gel. Blots were 
hybridized to the 574bp probe which covers exons 5-9. The probe was cloned with primers 
mTrim24-SB-F and mTrim24-SB-R (Appendix 1) and labeled with radiolabeled Phosphorus-32 
(32P) and purified using the Promega Prime-a-gene labeling system to following the 
manufacturer’s instructions. 
 
2.3 PCR analysis of mouse genotypes  
Transgene positive progeny were confirmed by LacZ staining and PCR genotyping.  Tissue 
samples (ear punches or toe snips) were taken from mice at P10 (post birth day 10) and 
submerged in 100uL LacZ staining solution (0.1M phosphate buffer [pH7,3] 2mM MgCl2, 
0.01% sodium deoxycholate, 0.02% Nonident P-40, 5mM potassium ferricyanide, 5mm 
potassium ferrocyanide, 1mg/mL X—gal) and incubated for 1 hour at 37C while shaking[50]. 
Those pups staining blue were considered LacZ positive while those with no apparent change 
in color were considered lacZ negative.  
Transgene presence was further confirmed by PCR genotyping. Tissue (toe snips or ear 
punches) were isolated from P10 mice and submerged in 100ul tail digestion buffer 
(Phosphate Buffered Saline (PBS), 0.2% Tween-20, 10ug Proteinase K) and digested overnight 
at 37C while shaking. After digestion, Proteinase K was heat inactivated by boiling at 100C 
for 30mins.  Resulting DNA samples were used for genotyping.  Transgene presence was 
determined by PCR using primers p23 and p24. PCR conditions were as follows: 95C for 3 
minutes pre-heating, 35 cycles of 95C 30 seconds, 60C for 30 seconds, 72C for 1 minute, 
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then 72C 5 minutes. The 600-base pair Flag-TRIm24 DNA fragment was visualized by agarose 
gel electrophoresis.  
 
 
2.4 Cre recombination of TRIM24 transgene in the mouse mammary gland  
To remove the loxP flanked stop cassette in transgenic mice in the mammary gland, Flag-
TRIM24Tg/0 mice were bred to MMTV-CreTg/Tg mice (Line D, from Jackson Laboratories). Mice 
carrying the Cre transgene were confirmed by PCR genotyping with primers Cre1 and Cre2. 
PCR conditions were as follows: 95C for 3 minutes pre-heating, 30 cycles of 95C 30 seconds, 
60C for 30 seconds, 72C for 1 minute, then 72C 5 minutes. The 150base pair Cre-
recombinase DNA fragment was visualized by agarose gel electrophoresis. 
 
2.5 Introducing p53 heterozygosity into the Trim24 Conditionally Over-Expressing 
(Trim24COE) mice  
To introduce Trp53 heterozygosity into the TRIM24COE mouse background, TRIM24COE mice 
were bred to Trp53-/- mice (129 inbred, Jackson Laboratories). Trp53 genotype was determined 
by PCR genotyping with primers X6, X7, Neo (Appendix 1). PCR conditions were as follows: 
95C for 4 minutes pre-heating, 40 cycles of 95C 45 seconds, 56C for 45 seconds, 72C for 1 
minute, then 72C 5 minutes. A single 450 base pair band appeared from wild type animals, a 
single 575 base pair band appeared for homozygous deleted animals; heterozygous animals 
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produced bands at both sizes. Only mice wild type or heterozygous for Trp53 were used in the 
subsequent studies.  
 
 
2.6 Western blot analysis of Trim24COE genotypes  
To confirm protein expression in transgenic mouse mammary glands, tumors and tumor-
derived cell lines protein lysates were prepared as follows. For tissues: frozen tissues were 
cryo-pulvarized in liquid nitrogen using a mortar and pestle. On average 100mg of tissue was 
subjected to lysing with RIPA buffer (1% NP-40, 0.5% deoxycholate, 0.1% SDS, in 1X PBS) and 
sonicated on 40% power for 5 seconds, intermittently resting, for a total of 3 rounds. The lysate 
was then rocked at 4C on the for 1 hour, then centrifuged for 15 minutes at 13K rpm at 4C 
to pellet cell debris.  100ug total protein lysate was diluted with 5X SDS loading dye, boiled for 
3 minutes, and resolved by electrophoresis on a 10% SDS-PAGE gel. Resolved proteins were 
transferred to a nitrocellulose membrane and immunoblotted overnight with primary 
antibody. Antibodies and dilutions are as follows:TRIM24 (Protein Technologies 1:2,500), p53 
(393-FL-HRP Santa Cruz 1:2,000), Flag (M2(Flag)-HRP, Sigma, 1:2,000). Membranes were 
washed and incubated in secondary antibodies (anti-rabbit IgG, Millipore, 1:10,000) for one 
hour. Proteins were visualized using GE ECL or ECL-prime reagent (GE Healthcare).  
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2.7 RNA extraction and rtPCR  
Total RNA was isolated using the miRVana miRNA isolation kit, according to manufacturer’s 
protocol (Thermo Fisher). Briefly, tissues (mammary gland and tumor tissue) were cryo-
pulvarized in liquid nitrogen, weighed, then homogenized and lysed in 10 volumes tissue mass 
of manufacturers lysis buffer on ice until no visible clumps remained. RNA was extracted with 
acid Phenol-chloroform, then bound to the manufacturer’s column. RNA was washed twice 
then eluted with nuclease free water at 100C. Resulting RNA was measured via Nanodrop™ 
spectrometer. Total RNA prep was depleted of DNA with turbo DNase (Ambion). Briefly, RNA 
prep was eluted in 44uL nuclease free water; 5uL 10X Turbo DNase buffer and 1uL DNase was 
added and then incubated at 37C for 30 minutes. The volume was normalized to 100uL with 
Tris EDTA (TE) pH8 and extracted using acid phenol-chloroform, followed by an extraction with 
chloroform, and one wash with 70% ethanol in DEPC water. Resulting RNA pellet was dissolved 
in 50uL nuclease free water and A260/230 measured by Nanodrop™ spectrometer 
cDNA Synthesis 
cDNA was synthesized using the iScript Reverse Transcription Supermix (BioRad) following 
manufacturer’s instructions. Briefly, 1ug of RNA was combined with 4uL iSCRIPT and volume 
brought up to 20ul with nuclease free water. Reverse transcription was carried out in the 
thermocycler using the following settings: 25C for 5 minutes, 46C for 20 minutes 96C for 
1 minutes. Resulting cDNA was diluted 1:20 with sterile water prior to use in qPCR assay. 
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rtPCR conditions  
All rtPCR primers were designed to span two exons using the Oligo Architect software (Sigma) 
in conjunction with the Mouse Genome Informatics Database Ensemble (NCBI).  Sequence 
specificity for the primers was confirmed by the BLAST (NCBI) software. Stock solutions of 
primers were maintained at a concentration of 100Um in sterile water. Working solutions 
were made of a 1:10 dilution of stock solution.  Quantitative PCR experiments master mixes 
were made up as follows: for each well, 5uL Syber Green (BioRAD), 0.05uL each primer, 1.9uL 
sterile water and 3uL cDNA. qPCR reactions were carried out with the following conditions: 
95C holding for 5 minutes, 95C 30 seconds, 55-60C annealing (varies by primer set) for 30 
seconds, and 72C elongation for 30 seconds, repeat to step 2 for a total of 40 cycles. 18S 
ribosomal RNA was used for normalization. 
 
2.6 Histological and Immunohistochemical studies  
Paraffin embedded sections  
Tumor tissues were fixed in 10% neutral buffered saline at 4C overnight or up to 2 weeks. 
Fixed samples were processed by the MD Anderson Cancer Center Veterinary Medicine 
Pathology Core by dehydration in ascending concentrations of ethanol, and embedding in 
paraffin. Sections were cut to 5-10um thickness for immunohistochemical staining.  
Frozen tissue sections  
Inguinal mammary glands were dissected from female mice and flattened onto a glass slide 
and fixed in cold 4% paraformaldehyde in PBS for 30 minutes, washed twice for 10 minutes 
in 1X PBS, incubated in 30% sucrose overnight at 4C, then transferred into 1:1 
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OCT(Fisher):30% sucrose overnight at 4C. Tissues were then frozen in OCT and frozen on dry 
ice. Sections were cut to 10-15um, stored at room temperature for 48 hours to allow tissue 
to adhere to the slide, then stored at -80C until staining. On day of staining, sections were 
brought to room temperature, submerged in PBST (1% Tween-20) for 5 minutes. Sections 
were blocked in PBST with 3% Bovine Serum Albumin (Sigma) for 30 minutes at room 
temperature, sections were incubated in primary antibody diluted in PBST (TRIM24, 
Proteomes, 1:500) with BSA overnight at 4C, washed in PBS 3X 6 minutes, incubated in 
secondary antibody (anti-rabbit IgG 1:800) in PBS washed again in PBS 3X 6 minutes, excess 
liquid removed and mounted in mounting media with DAPI. 
 
Carmine Alum Staining  
Inguinal mammary glands were dissected from female mice, flattened onto a glass slide and 
fixed in cold 4% paraformaldehyde in PBS overnight. The following day, glands were washed 
in PBS 3x 10 minutes then submerged in carmine alum staining solution (4mM carmine, 
10mM aluminum potassium sulfate) at room temperature overnight or until staining was 
thoroughly accepted by the tissue. Tissues were then dehydrated through increasing 
concentrations of ethanol (70%, 95%, 100%) for one hour each, cleared in Histoclear (National 
Diagnostics) at room temperature overnight and stored in 100% toluene.    
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Immunohistochemistry 
All hematoxylin and eosin (H&E) staining was performed by the MD Anderson Department of 
Veterinary Medicine Histology Core. Immunohistochemistry for Flag (Sigma, 1:5000), ER (Santa 
Cruz, 1:500), PR (Santa Cruz, 1:4000), ErbB2 (Santa Cruz, 1:500), K8 (Developmental Studies 
Hybridoma Bank, 1:500), K14 (Covance/BabCo, 1:500),E-cadherin (Santa Cruz, 1:100), Vimentin 
(Abcam, 1:500), and TRIM24 (Proteomes, 1:500) was performed by the MD Anderson cancer 
Center Research Histology Pathology and Imaging Core using the following protocol. Briefly, 
sections were deparaffinized and dehydrated in xylene followed by graded alcohols (100%, 95% 
EtOH) to water. Endogenous peroxidase activity was blocked by incubation in 3% H2O2 in water 
for 10 minutes, followed by antigen retrieval in boiling 10mM citrate buffer pH6.0 for 20 
minutes. Tissues were blocked in blocking reagent(Biocare) for 10 minutes followed by primary 
antibody incubation overnight at 4C. Slides were then washed in PBS, incubated with anti-
rabbit-HPR (Dako) for 30 minutes at room temperature and washed again, with PBS. 
Colorimetric stain precipitation was performed by incubation with DAB. Finally, slides were 
washed, counterstained, dehydrated, and covered with mounting media and a glass cover slip 
prior to visualization.  
2.7 Tissue Culture assays 
Isolating Mammary Gland (MG) epithelial cells and tumor cells 
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Upon harvesting, tumors were divided into sections for paraffin embedding, frozen sections, 
freezing for protein and RNA isolation and the remainder for cell isolation. Sections designated 
for cell isolation were harvested into DMEM with 10% FBS and 100U/mL penicillin/streptomycin. 
Cells were minced with a #10 spatula until no identifiable pieces remained, then digested in 
10mls digestion media (DMEM-F12, 250u/ml hyaluronidase (Sigma), 3mg/ml collagenase 
(Sigma),  100U/mL penicillin/streptomycin, 100u/mL antibiotic-antimycotic) per gram of tissue 
while shaking at high speed for 1-3 hours at 37°C. Cells were filtered through a 40um sterile filter 
and centrifuged at 1.5K rpm for 10 minutes at 4°C. Cells were washed 4 times in DMEM/F12 by 
centrifuging at 1.5K rpm for 5 seconds.  Resulting epithelial-enriched suspensions were then 
plated onto 60mm tissue culture dishes in complete medium (DMEM, 10% FBS, anti/anti) at 
37°C. Cells were allowed to grow to confluence, during which time observable colonies were 
formed. These colonies were then subjected to differential trypsinization. Cells were washed 
twice with PBS, 4 ml 0.4% trypsin was placed on the cells, then all but 1mL was aspirated off. 
Plates were then incubated at 37C for 2 minutes, removed and gently tapped to specifically 
release colonies, leaving behind mesenchymal and fibroblast like cells. The resulting population 
was termed epithelial enriched and was then plated onto a new dish and cultured subsequently 
in conditioned media. Conditioned medium was made by removing medium from tumor-derived 
cells, filtering through a 40um filter and mixing 1:1 with fresh tumor cell culture medium. 20 
cells lines were isolate in total; they are summarized in Appendix 4.  
 
Colony Formation 
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Cells were plated at a density of 500 cells per well in 6-well plates and allowed to grow, 
undisturbed for 10 days. Resulting colonies were washed twice with PBS then stained with 0.05% 
crystal violet for 5 minutes at room temperature while shaking. Plates were then washed with a 
slow, steady flow of tap water and dried overnight. Colonies were counted manually.  
 
Cell fractionation 
Cells in culture were washed with PBS, trypsinized and harvested. 2.5X107 cells were counted 
and used for isolation of sub-cellular fractions. Cells were washed with cold PBS, then 
resuspended in buffer A (10mM HEPES pH7.9, 10mM KCl, 1.5mM MgCl2, 0.34M sucrose, 10% 
glycerol, 0.1% NP40, 1mM DTT, EDTA free protease inhibitor (Thermo Fisher)), by pipetting up 
and down to lyse cells. One fifth of this lysate was collected as whole cell lysate and immediately 
heated at 95C for 10 minutes in 5X Laemmli loading buffer. The remaining lysate was set on ice 
for 8 minutes, then centrifuged at 2K Xg for 2 minutes. Cell pellet was washed with buffer A 
minus NP40 and pipetted with wide bore tip and centrifuged at 2K Xg for 2 minutes. The 
supernatant and previous supernatant were combined and immediately boiled in Laemmeli 
buffer for 10 minutes. This was collected as the cytosolic fraction. The soluble nuclear fraction 
was collected by resuspending the nuclear pellet in buffer B (3mM EDTA, 0.2mM EGTA, 1mM 
DTT, protease inhibitor cocktail), pipetting with wide bore tip, incubating on ice for 30 minutes 
and centrifuging at 2K Xg for 2 minutes. The remaining chromatin bound proteins were released 
by heating the chromatin pellet in buffer B and Laemmeli buffer at 95C for 10 minutes. All DNA 
was sheared by brief sonication prior to gel loading.  
Proliferation  
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Cells were plated to a density of 1,000 cells per well in a 24-well plate, in triplicate, for each day 
of counting. On day of counting, media was aspirated and well washed once with PBS, then 
200uL of trypsin added and incubated at 37C for 5 minutes. Trypsin was neutralized with 800uL 
complete media and cells re-suspended to a single cell suspension. 200uL was used to count 
cells using the Beckman Coulter particle counter and cells per milliliter were extrapolated. 
2.8 Genome-Wide Assays 
DNA Isolation for Exome-sequencing 
 Tumor tissues were cryo-pulvarized using a mortar and pestle in liquid nitrogen. 
Crushed tissues were put into 250uL PBST with 2.5uL proteinase K and incubated at 37C 
overnight, shaking. DNA was isolated through one round of phenol-chloroform 
extraction, followed by two rounds of chloroform extraction. DNA was precipitated in 
100% ethanol and 3MNaOAc at -80C overnight, pelleted for 20 minutes by 16krpm 
centrifugation, washed once in 70% ethanol, dried, and resuspended in sterile water and 
measured by Nanodrop spectrometer. 
 
 Chromatin Immunoprecipitation for ChIP-sequencing 
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Cells were grown on 15-cm plates to 75% confluency. Proteins were fixed with disuccinimidyl 
gluterate (DSG, Thermos Scientific) for 15 minutes, washed 3 times with PBS. DNA was fixed with 
1% formaldehyde for 10 minutes at room temperature, fixing stopped with 125mM glycine for 
5 minutes at room temperature. Cells were washed twice with cold PBS then pelleted at 2K rpm 
for 5 minutes at 4°C. Cells were lysed in cell lysis buffer (5mM PIPES pH8.0, 85mM KCl, 
0.5%NP40, Protease Inhibitors (PIs) and Phenylmethanesulfonyl fluoride (PMSF)) on ice for 15 
minutes with occasional vortexing then centrifuged at 5K rpm for 5 minutes. Nuclei were lysed 
in nuclei lysis buffer (50mM Tris pH8.0, 10mM EDTA, 1% SDS, PI’s, PMSF) on ice for 10 minutes 
followed by 40 cycles of sonication on the biorupter. Lysates were centrifuged at 13K rpm for 15 
minutes at 4° to remove cellular debris. Lysates were pre-cleared with normal sheep IgG 
antibody (2.5ug, Millipore) for 1 hour at 4. Non-specifically bound proteins were removed by 
rocking lysates with 40uL of 50% Protein A Sepharose bead slurry (GE Healthcare) for 1 hour and 
spinning at 5K rpm for 2 minutes at 4°C. Lysates were rocked incubated with 5ug TRIM24 
antibody (Protein Technologies) overnight at 4°C. Antibody aggregates were removed by 2 
minute centrifugation at 13K rpm at 4°C. Protein complexes were recovered by incubation with 
40uL Protein A beads for 2 hours at 4°C. Beads were washed as follows in 5 washes for 10 
minutes at 4°C followed by centrifugation at 5k rpm for 2 minutes at 4°C. The washes were as 
follows: RIPA (50mM Tris pH8.0, 150mM NaCl, 0.1% SDS, 0.5% deoxycholate, 1% NP40, 1mM 
EDTA), high salt buffer (50mM Tris pH8.0, 500mM NaCl, 0.1% SDS, 0.5% deoxycholate, 1% NP40, 
1mM EDTA), LiCl wash (50mM Tris pH8.0, 1mM EDTA, 250mM LiCl, 1% NP40, 0.5% 
deoxycholate), TE with PIs and PMSF, TE. Resulting protein-DNA complexes were depleted of 
RNA with RNase A for 30 minutes at 37°C. Proteins were digested with 7.5ug Proteinase K in 10% 
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SDS at 37°C for at least 4 hours, then reverse crosslinked overnight at 65°C. DNA was extracted 
by phenol-chloroform extraction – two rounds of phenol:chloroform (1:1), followed by one 
round of chloroform. DNA was precipitated in two volumes 100% ethanol, 1/10 volume 3M 
NaOAc pH5.2, and 20ug glycogen at-20°C for at least 2 hours, centrifuged for 20 minutes at 13K 
rpm for 20 minutes. The resulting pellet was washed twice with 70% ethanol, air dried, and 
resuspended in 50uL sterile water.  DNA was sequenced using the Illumina HiSeq2000.  
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Chapter 3: TRIM24 promotes in early mammary gland development  
3.1 Introduction 
The hormone receptors ER, PR, and PrlR are essential for proper mammary gland 
development and function[18]. Each receptor plays an important, yet distinct role at 
each developmental stage from birth, through puberty, pregnancy, lactation, and 
involution [51].  The majority of mammary gland development occurs postnatally, 
beginning with puberty. In the mouse, the ovaries secrete hormones which regulate 
mammary gland development, beginning at 3 weeks of age and continuing through 
puberty and adulthood, oscillating through the estrous cycle, pregnancy, and lactation 
[52]. A 2006 study showed that ER in the luminal epithelial cells of the mouse mammary 
gland is essential for development beyond the rudimentary ductal structure present at 
birth [53]. Estrogen signaling through luminal ER, initiated at puberty, controls 
elongation and bifurcation of the duct [17]. At the onset of puberty, at approximately 6 
weeks of age in the mouse, progesterone is secreted from the ovaries and binds to its 
receptors, Progesterone receptor-A and –B (PR-A, PR-B), which in turn up-regulate the 
RANKL pathway. An elegant study utilizing isoform-specific deletions of PR illustrated that 
PR-B, but not PR-A, is essential for side branching of the mammary gland and maturation 
of the alveoli (alveogenesis). Finally, alveologenesis and lactogenic differentiation that 
occurs in the mammary gland in response to pregnancy and lactation is regulated by 
prolactin [17].  
 30 
TRIM24 has been shown to co-activate ER-response genes through its LXXLL motif, and 
has also been shown to bind the PGR promoter by global analysis in MCF7 cells [32]. 
These studies led me to nominate TRIM24 as a potentially essential protein in the 
regulation of mammary gland development and function.  
TRIM24 is a non-essential gene for viability and fertility, as either germline or conditional 
hepatic deletion yield viable, fertile mice, which develop hepatocellular carcinoma (HCC) 
[49]. Prior to developing HCC at an average age of 9 months, these animals experience 
increased inflammation and damage of the liver, beginning at 8 weeks of age. 
Intriguingly, Trim24-/- mice have statistically less abdominal fat than their wild type 
controls due to a down-regulation of de novo lipid synthesis and lipid storage genes. As 
the mammary gland is comprised primarily of adipose tissue, I determined whether loss 
of Trim24 expression led a reduction of mammary fat and altered development of the 
Trim24-/- mammary gland in the Trim24-/- mouse model, previously established in the 
laboratory [49]. 
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3.2 The TRIM24-/- Mouse  
 To confirm loss of Trim24 expression in the mouse mammary gland, RNA was extracted 
specifically from mammary gland tissues and assayed for Trim24 expression, as 
compared to aged matched wild type mice (Figure 1).  The absence of transcript 
expression indicates that Trim24 was in fact deleted in the mammary gland. We further 
confirmed the loss of TRIM24 expression by immunohistochemistry in the mammary 
gland of 2-month-old mice. While TRIM24 is typically detectible in the luminal epithelium 
and stroma of developed glands as well as terminal end buds, the Trim24-/- mice have 
no expression in either structure (Figure 1).  
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Figure 
5 | 
TRIM24 Expression in the mouse mammary gland. A. qRT-PCR performed on mammary 
glands demonstrate a loss of Trim24 expression. B. Immunohistochemistry for TRIM24.  
In WT animals, TRIM24 is expressed in the luminal epithelium of mature mammary 
glands (top panel) and in the Terminal End Buds (bottom panel). This expression is lost in 
the Trim24-/- mammary gland (right panels).   
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3.3 Trim24-/- mouse mammary gland phenotype 
To uncover the role of TRIM24 in the developing mammary gland, we surveyed a number 
of Trim24+/+ and Trim24-/- animals during the early stages of mammary gland 
development to determine if there were any significant differences between the two 
groups. We found that, beginning at 3 weeks, the initiation of mammary gland ductal 
elongation, regulated by ER [7], was delayed in Trim24-/- mice compared to wild type, as 
measured by the average distance of the furthest duct from the initiating branch in a 
carmine alum stained whole mounted mammary gland (Figure 2). In contrast, Trim24 
heterozygous animals had no appreciable difference in mammary gland development 
compared to wild type mice.  Interestingly, Trim24-/- mice display a significant delay of 
ductal elongation at 4 and 5 weeks of age. However, this delay in growth of the TRIM24-
/- mammary gland is completely undetectable by 6 weeks of age. Intriguingly, this time 
point corresponds with the onset of progesterone secretion and subsequent PR-driven 
transcription and ductal branching [54].    
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Taken together, these data suggest that TRIM24 has a role in the early, ER-mediated 
development of the mouse mammary gland. However, the influence of TRIM24 is 
diminished with the onset of progesterone signaling, suggesting that TRIM24’s major 
hormone receptor partner in the mammary gland is ER and its function is most important 
in the very early stages of development.  Additional studies are needed to ascertain the 
molecular basis for these observations. 
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Figure 6 | Trim24-/- mice have delayed mammary development. A. Carmine alum 
staining of whole mount mouse mammary gland at 3, 4, 5, and 6 weeks of age. B. 
Quantification of the average distance past the lymph node in 5 week females (n=3). 
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Chapter 4: TRIM24 as a driver of mammary tumorigenesis 
4.1 Introduction 
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High levels of TRIM24 have been associated with human cancers in a number of organs, 
including breast [32], bladder [42], glial cells [55], head and neck [46], prostate[47], 
gastric [43], and liver [44]. In a study of castration-resistant prostate cancer (CRPC), the 
Brown laboratory found that TRIM24 activates proliferation-promoting genes as a co-
regulator of Androgen Receptor in prostate cancer cells, and that TRIM24 over-
expression is predictive of disease recurrence in patients [47]. Our laboratory showed 
that TRIM24 over-expression in a non-transformed immortalized human mammary 
epithelial cells (iHMECs) causes significant transformation toward tumorigenic capacity 
[48].  With an average 3-fold increase in TRIM24 expression, these cells undergo 
accelerated proliferation, gain the ability to grow in soft agar, have a significant cell cycle 
shift from G1 to S-phase, and form xenograft tumors in mice. While this study showed 
very elegantly the potential of TRIM24 as an oncogenic driver in cultured mammary 
epithelial cells, previously immortalized by chemical mutagenesis, they did not assess 
TRIM24’s oncogenicity in vivo. As most findings in the clinic are largely correlative and 
the iHMEC and CRPC studies focus on in vitro models, there is a significant gap in 
knowledge in the field regarding the ability of TRIM24, as a single causative agent, to 
drive tumor progression in vivo. Our study aims to address this gap by determining 
TRIM24’s potential to drive mammary tumorigenesis in a physiologically relevant mouse 
model.  
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4.2 Generating the TRIM24 conditional over-expressing mouse model 
With the goal of determining the ability of TRIM24 to drive mammary tumor 
development in vivo, we constructed a conditional over-expression mouse model, which 
allows temporal and spatial control over the expression of exogenous TRIM24, as 
determined by expression of Cre. Our mouse model was generated in collaboration with 
the Behringer laboratory and took advantage of the piggyBAC transposase technology.  
Initially discovered and sequenced in insects in 1989, the piggyBac superfamily arose in 
nature as a mechanism to create new advantageous genes [56].    Since 1995, piggyBac 
transposons have been used as a tool for genetic manipulations involving insertion of 
non-host DNA into the genomes of multiple organisms [57]. Over the past 2 decades, 
investigators have taken advantage of this system to make genetic manipulations in 
multiple model systems, including human embryonic stem cells [58], mouse embryonic 
stem cells [59], and rats [60]. piggyBac is well suited for transgene insertion in 
mammalian systems due to its relatively high transposition activity [61] and ability to 
efficiently insert fragments of DNA as large as 14kb. As we were interested in increasing 
the levels of TRIM24 to clinically relevant levels while making a minimal disruption to the 
mouse genome, we took advantage of this system. 
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A 3xFlag epitope tag was added to the carboxyl-terminus of TRIM24 open reading frame 
and inserted into the pENTR directional-TOPO (entry vector) by TOPO cloning and 
subsequently recombined into p2lox-GW (gateway destination vector) downstream of a 
loxP-flanked B-galactosidase polyA fusion stop cassette, under the control of the human 
Ubiquitin C (UbC) promoter. Mice conditionally over-expressing Flag-TRIM24 were 
generated by mobilization of the resulting p2loxGW_TRIM24 transposon vector into the 
FVB mouse germline by co-injection of the pcDNA3-modified piggyBac transposase 
mRNA with p2loxGW_TRIM24 plasmid into the pronucleus of 180 single cell embryos 
(Figure 3).  The injected embryos were implanted into six CD1 pseudo pregnant females; 
of the resulting pups seven were positive for the Trim24 transgene by lacZ staining and 
PCR genotyping. Intensity of B-galactosidase staining, which was used as a measure of 
expression level, varied amongst animals.  Of four mice with ubiquitously stained ear 
punches, two were chosen as founders – lines 821 and 804. Confirmation of a single site 
of integration was obtained through Southern blotting of genomic DNA from the 
founders and their offspring (Figure 8). Furthermore, single insertion was supported by 
crossing first generation offspring (F1) of these founder mice to wild type FVB mice, and 
staining embryos harvested at 13.5dpc for lacZ expression. From these crosses, we find 
that on average 50% of the animals were lacZ positive, providing further evidence for a 
single site of insertion. Intriguingly, at this time point, only the progeny of founder 821 
demonstrated ubiquitous lacZ expression (Figure 10). This suggests that only one line 
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may be suitable for our studies as our goal is to have a mouse that can over-express 
TRIM24 in any tissue when crossed with the appropriate promoter-driven Cre. However, 
due to differences in genomic landscape and gene activity from embryos to adults, we 
could not rule out the possibility of non-ubiquitously stained animals having the ability 
to express in the mammary gland postnatally or vice versa. 
To confirm transgene expression in our tissue of interest, the mammary gland, I 
performed lacZ staining on mammary glands of 10-week-old mice. As a control for 
mammary gland epithelial expression, I used the LMXb1-LacZ mouse a gift from the 
Johnson laboratory. This reporter mouse was previously used to map the expression of 
the LMXB1 transcription factor in the mouse mammary gland. This study revealed that 
LMXB1 is highly expressed during all stages of mammary gland development [62]. While 
wild type mice have no lacZ expression and control, LMXb1-LacZ mice have extremely 
robust lacZ staining, mice derived from founder #804 are completely devoid of lacZ 
positivity in the mammary gland, while mice from line 821 have quite modest expression 
in the mammary gland (Figure 11). These data led us to move our study forward with a 
single mouse line, 821.  Subsequent breeding was carried out through the progeny of 
mouse #821 and genotyping was confirmed by PCR (Figure 12).   
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Figure 7 | piggyBac Flag-TRIM24 Conditional Over-expression construct.  A. p2lox-
Gateway vectors used for cloning the transposon. B. Flag-TRIM24 transposon vector and 
piggyBac (mPB) transposase. IR: inverted repeat sequences, recognized by piggyBac, 
cHS4: chick beta-globin hypersensitivity insulator sequences, UbC: ubiquitin C promoter’ 
B-geo 3XpA: Beta-galactosidase fused to polyadenylation site, Cm: Chloramphenicol 
resistance gene, cdB: ccdB gene, Amp: ampicillin, Kan: kanamycin, CMV: cytomegalovirus 
promoter. 
 42 
 
 
 
 
 
  
 
 
Figure 8 | LacZ Ear Punches of Founders. A. Ear punches of 8 offspring generated from 
in vitro-fertilized mice. B. Table of chosen founders and subsequent G1 offspring.  
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Figure 9| Southern blotting founders to confirm single copy insertion. A. Schematic of 
transposon, shown are Nde1 digestion site and probe target location. B. Southern blot 
of founders. 
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Figure 10 | Transgene expression in mouse embryos and mammary gland. Lac Z stained 
pups from Flag-TRIM24Tg/o X FVB WT cross from founder 821, upper panel and 804, 
lower panel.  
 
770 (F 804) 
722 (F 821) 
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Figure 11 | Transgene expression in mouse mammary gland. LacZ stained, whole 
mounted mammary gland from control (LMX1 and WT) mice and progeny of two 
transgenic mice (770 – F804, 722 – F821) at 2 months of age.  
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Figure 12 | PCR Genotyping. PCR genotyping in WT and transgenic animals showing a 
single band at 700bp.  
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4.3 TRIM24 over-expression in the mouse mammary gland 
The MMTV-Cre mouse is a well-established model for expression in the mouse 
mammary gland. There are two independent lines which initiate and reach full 
expression at different times, line A in utero, line D approximately 22-days [63]. We 
chose line D for its postnatal initiation of expression and attainment of full expression 
by 6 weeks. The expression pattern of these animals has been previously detailed, 
showing varied expression between glands in both the luminal epithelium and 
myoepithelium, with localization to either the nucleus or cytoplasm exclusively, or both 
sub-cellular compartments, simultaneously (Figure 14) [63]. As TRIM24 is expressed in 
both the nucleus and the cytoplasm of human breast cancer cells [32], this model is 
extremely relevant to mimic the expression pattern seen in human disease.   
As both male and female transgenic mice were viable and fertile, no preference was 
made for breeding. MMTV-Cre animals were bred to transgene positive animals and 
allowed to age. Genotyping to confirm the transgene presence was carried out as 
previously noted and confirmation of Cre-recombinase transgene was also carried out 
by PCR (Figure). Mammary gland over expression of Trim24 was confirmed by qRT-PCR 
(Figure), immunoblotting for flag epitope and TRIM24 (Figure), and 
immunohistochemistry for Flag in the mammary gland (Figure).  On average, we saw 
2.5-3 times higher transcript expression in the mammary gland and 5 times higher 
protein expression, although there is considerable variation between animals.  
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Figure 13 | Breeding Scheme. Flag-Trim24Tg/o mice are bred to MMTV-CreTg/Tg mice, 
resulting in Flag-TRIM24Tg/o;MMTV-CreTg/o mice, hereafter referred to as Trim24COE. 
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Figure 14 | MMTV-Cre published expression Pattern. The MMTV promoter is used to 
drive inducible expression of Cre recombinase in the luminal epithelium in mouse 
models.  Lac-z staining in MMTV-Cre mammary glands.  A) low magnification of 
mammary gland, showing glands (arrows) and lymph node (arrowhead) B) Luminal 
epithelial staining (arrow) and myoepithelial staining (arrowhead) C) high magnification 
of gland staining primarily in the myoepithelium D) high magnification of mammary 
gland staining primarily in the luminal epithelium E) High magnification of robust 
staining in the entire mammary gland F) negative control showing no staining in 
glands(arrows) or lymph node (arrowhead). Printed with permission from Wagner et 
al. Transgenic Research 2001 
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Figure 15 | RNA and Protein Expression of TRIM24 in Mammary Gland. A) qPCR of 
TRIM24 transcripts in mouse mammary gland with average 2.5-fold increase. p=0.07, 
n=5. B) Western blot analysis of TRIM24 and Flag in mouse mammary gland. 
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Figure 16| Flag expression in Trim24COE mammary gland. Flag expression is present in 
both the luminal epithelium and myoepithelium with varying patterns between glands.  
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4.3 Increasing Tumorigenic Potential by Depletion of Trp53 
TRIM24 was identified as a negative regulator of p53, by virtue of its RING domain’s E3-
ubiquitin ligase activity [37]. This regulation of p53 occurs in response to DNA damage 
[38]. In an effort to accelerate potential tumor development we crossed Trim24COE 
animals into a Trp53+/- background. Initially, Trim24COE were bred to Trp53-/- mice to 
generate Trp53+/-;Flag-Trim24Tn/0;MMTC-CreTg/0 (p53+/-Trim24COE) female mice. 
Genotyping to confirm Trp53 status was performed in addition to Trim24 transgene and 
Cre genotyping (Figure 17). An aging cohort was established with the resulting female 
mice.  
 
4.3 Trim24COE mice develop atypical hyperplasia 
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Robust Cre-recombinase expression in the mammary gland occurs by 6 weeks of age in 
the MMTV-CreTg/Tg line D [63]. We began assessing the consequence of increased 
epithelial TRIM24 expression at 10 weeks of age. Hematoxylin and Eosin (H&E) staining 
revealed that Trim24COE animals developed atypical hyperplasia which could be 
visualized by increased expansion of the myo- and luminal epithelial cell layers (Figure). 
Additionally, these animals displayed increased ductal side branching as visualized by 
whole mount carmine alum staining. Both the hyperplasia and increased branching 
phenotypes were retained in TRIM24COE animals through 13 months of age, suggesting 
that this phenotype is not a transient one and is governed by the over-expression of 
TRIM24.  
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In our aging cohort, Trim24COE mice developed mammary tumors as early as 8 months 
of age with a range up to 21 months of age. The penetrance of this phenotype is 48.8% 
of animals developing tumors prior to death. The median tumor-free survival of 
Trim24COE mice is 540 days compared to their MMTV-CreTg/0 controls, which had an 
undetermined median survival age due to no tumor incidence. The deletion of one allele 
of Trp53 did not alter the penetrance of the phenotype, but reduced median tumor-free 
survival to 330 days while that of Trp53+/-;MMTV-CreTg/0 control mice is 600 days. Of 
the twenty-one  animals that developed tumors there were two metastases, both to the 
lung. Pathologic examination of the tumors revealed that the animals developed an array 
of tumor lesions of the breast, including adenoma (5%), adenocarcinoma (10%), 
pleiomorphic undifferentiated sarcoma (5%), spindle cell sarcoma (5%), and 
carcinosarcoma (70%). Appendix 3 summarizes the necropsy records of each tumor and 
peripheral organs.   
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Figure 17 | TRIM24 over-expression increases ductal branching and hyperplasia. A) H&E 
(upper panel) and carmine alum staining (lower panels) of mammary glands at 2 months 
(i,ii,v, and vi) and 13 months (iii, iv, vii, and viii). B) Representative hematoxylin and eosin 
staining of hyperplasia in mouse mammary glands upon aging.  C) Quantification of 
atypical hyperplasia in aging cohort.  
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4.4 TRIM24 over expressing mice develop mammary cancers 
Mouse tumors were stained for classic biomarkers to reveal the subtype of each tumor, 
ER, PR, ERBB2 (Her2). Of the animals assessed, all were negative for ER and ERBB2, but 
positive for PR (summarized in Table). Expression of the transcripts of these markers 
was assessed by qRT-PCR and corresponded with our findings by IHC (Figure). 
Interestingly, all tumors of the TRIM24 over-expressing phenotype, whether wild type 
or heterozygous for Trp53, stained positively for Flag-TRIM24 but not uniformly. This 
suggests that although TRIM24 over-expression does play an important role in 
promoting tumorigenesis, it may do so by affecting gene expression in both a paracrine 
and autocrine fashion. Based on these analyses, we concluded that our TRIM24-driven 
model and TRIM24 over-expression represents an ER-PR+Her2- phenotype. These data 
are somewhat contradictory to the finding that TRIM24 is positively correlated with 
expression of ER and Her2 when assessed by IHC in a commercially available breast 
tumor microarray [48]. It should be noted however, that a meta-analysis revealed that 
after neoadjuvant therapy hormone receptor status of tumors can change, so that the 
hormone receptor status a person presented with at initial biopsy may not always be 
concordant with hormone receptor status of biopsies taken after treatment [64]. Many 
samples on breast tumor arrays are post-therapeutic. It is therefore reasonable to 
consider a scenario in which the hormone receptor status of the tumors on 
commercially available TMAs is may be discordant with the status of the tumor at 
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presentation.  As our mouse model, has undergone no therapy of any kind, this caveat 
should be considered when discussing any application of TRIM24 expression 
correlation with hormone receptor status in patients.  
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Figure 18 | TRIM24 over-expression drives heterogeneous mammary tumor spectrum 
A) Tumor free survival curve of MMTV-CreTg/0 mice compared to Trim24COE mice B) 
Tumor free survival curve of Trim24COE compared to Trp53+/- mice. C) Tumor free 
survival curve of Trp53+/- and p53+/-Trim24COE mice. D) Tumor free survival curve of 
all mouse cohorts.  
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Figure 19 | Mouse Gross Pathology. Representative images of Trim24COE and Trp53+/-
;Trim24COE mice with tumors. Black arrows indicate mammary tumors.  
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Figure 20 | Representative images of H&E stained tumor sections from the Trp53+/-
;Trim24COE cohort. Present are carcinoma (i), undifferentiated malignant sarcoma (ii), 
adenocarcinoma (iii), ductal carcinoma in situ (DCIS, iv), adenoma (v), and 
carcinosarcoma (vi). 
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Figure 21 | Western Blot analysis of TRIM24 levels in tumors and matched uninvolved 
mammary gland. MG: Mammary gland, T: Tumor 
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Figure 22 | Tumor hormone receptor status.  Representative image of 
immunohistochemistry for Flag, ER, PR, and ERBB2 in individual tumors. 
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Figure 23 | TRIM24 is highly expressed in human breast cancer patients TRIM24 
immunohistochemistry on TMA of Tumors and normal breast tissue. IDC: invasive ductal 
carcinoma, ILD: invasive lobular carcinoma, NB: normal breast tissue 
 
 
 
. 
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4.5 TRIM24 over-expression drives a metaplastic phenotype 
 
Pathological examination of mouse tumors revealed that 58% of TRIM24COE and 60% 
of Trp53+/-TRIM24COE tumors displayed histological patterns consistent with 
carcinosarcoma - a rarely diagnosed, highly aggressive form of breast cancer that is not 
well understood in the clinic and vastly understudied in the laboratory. 
Carcinosarcomas have historically been diagnosed by histological evidence of two cell 
types, one with epithelial characteristics (carcinoma) the other displaying 
morphological signature of mesenchymal or stromal cells (sarcoma) [65]. Although little 
is known about the origin or drivers of these tumors, metaplastic carcinomas of the 
breast represent a subset of triple negative breast tumors that have a significantly 
higher morbidity rate than invasive ductal carcinoma [66] and are correlated with 
increased expression of classical epithelial-to-mesenchymal transition (EMT) markers 
than other subtypes of breast cancer [67]. EMT is a process by which epithelial cells 
undergo an altered pattern in gene expression, which leads them to take on a 
phenotype that more closely resembles that of mesenchymal cells – a process that 
while essential for successful embryonic development has been implicated in the 
progression of many tumor types [68]. The ultimate measure of EMT induction is loss 
of E-cadherin, with additional readouts of EMT that include increases in the levels of N-
cadherin (CDH2) and vimentin.  With many molecular roads to achieve EMT, the most 
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highly studied are regulated by transcription factors Twist1, SNAI1, and Zinc Finger 
Proteins Zeb1 and Zeb2.  Because EMT is so tightly correlated with metaplastic 
carcinomas of the breast, we assessed the presence of these markers in murine Trim24 
COE tumors defined as carcinosarcoma by our pathologist. Protein expression of E-
Cadherin, Vimentin, and Keratins 8 and 14 was determined by immunohistochemical 
staining in tumors (Figure 24). We found variation in Flag-TRIM24 expression 
throughout the tumors. While E-Cadherin was detectible, the levels were very low; 
conversely, Vimentin staining was robust. K8 and K14 were also present in tumors at 
varying intensities. K8 staining generally being more robust that K14. 
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Figure 24 | EMT gene expression in Trim24COE tumors IHC. Representative image of 
immunohistochemistry for Flag, E-cadherin, Vimentin, Keratin 8 and Keratin 14 in 
individual tumors. 
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4.6 Genetic alterations occur as a result of TRIM24 over-expression  
Metaplastic carcinomas of the breast (MpBC) are generally characterized as triple 
negative breast cancers. Various genome wide studies of MpBCs have identified 
frequent mutations in TP53, PIK3CA, PDL-1 and KDM6a amongst other mutations [26, 
69, 70]. In order to determine if the genetic alterations that occur in mouse 
carcinosarcomas, as a result of TRIM24 over-expression, are coincident with alterations 
in human metaplastic breast cancers, we performed whole exome sequencing on 12 
mouse tumors (7 Trim24COE carcinosarcomas, 2 Trp53+/-;Trim24COE 
carcinosarcomas, 2 Trp53+/- carcinosarcomas and 1 Trim24COE adenocarcinoma. In 
total, we found a total of 10,880 individual mutations across our 12 sequenced tumor 
samples.  
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Genomic comparison between only Trim24COE mouse carcinosarcomas (n=7) and 
human MpBCs (n=21) was performed using whole exome sequencing. Variant calls 
were higher in the mouse carcinosarcomas (5,975 unique variants and 4,869 genes 
impacted by mutations) compared to the human MpBCs (2,370 unique variants, 2043 
genes impacted by mutations).  Variants that existed in homologous genes were 
considered common variants (n=414). Unsupervised clustering of the mutation data 
revealed a subset of patients (n=5) whose tumors demonstrated significant similarity 
with Trim24CEO mouse tumors in pathway mutations, herein referred to as TRIM24-
like tumors (Figure 26). Targeted analysis of Trp53 uncovered no mutations in the 
mouse tumor samples, while 1 (20%) TRIM24-like human MpBC sample harbored TP53 
mutations versus 56% of the non-TRIM24-like samples with TP53 mutations (data not 
shown).  This finding suggests that tumors that over express RING-domain protein 
TRIM24, or tumors with a TRIM24-like variant profile, are capable of bypassing p53-
mediated tumor suppression by means other than TP53 mutation. We next looked for 
mutations in PI3K; while 29% of the human MpBCs harbored mutations in PIK3CA, none 
were seen in the TRIM24-driven mouse tumors.  However, 71% of the mouse tumors 
had mutations in homologs for other PI3K subunits (PIK3C2A, PIK3C2G, PIK3C3, and 
PIK3CG) (Figure 27). Thus, while the specific mutated gene may be discordant, it 
appears possible that similar pathways are affected.  
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 Integration of mutations, revealed by WES, and differentially expressed genes, 
profiled by RNA-seq, of Trim24COE tumors showed no mutations in down regulated 
genes from the top 500 deregulated gene list and a small subset (23) mutated genes in 
the upregulated gene list. The mutated genes fell into the following hallmark pathways: 
EMT, allograft rejection, inflammatory response, myogenesis, IL6/JAK/STAT3 signaling, 
apical junction, complement, IL2/STAT5 signaling. Though EMT was the most 
significantly mutated pathway, the genes mutated were not canonical EMT 
transcription factor genes but rather EMT-associated genes (COL6A3, SLIT2, ECM1, 
COL5A2, COL12A1, PCOLCE2, EFEMP2, and SERPINE2). These data suggest that the EMT 
observed in these tumors is driven primarily by TRIM24 transcriptional co-regulatory 
functions and not as a result of mutations caused by genomic instability.  
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Figure 25 | Exome-sequencing results. Average number of variants in tumors of each 
genotype. Trim24COE n=8, Trp53+/-;Trim24COE n=2, Trp53+/- n=2. 
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Figure 26 | Hierarchical clustering of mutated hallmark pathways in TRIM24COE mouse 
carcinosarcomas and human Metaplastic Breast Tumors  
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Figure 27 | Hierarchical clustering of PI3K, p53, and TRIM24-family genes in TRIM24COE 
mouse carcinosarcomas and human Metaplastic Breast Tumors  
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4.7 TRIM24 over-expression drives EMT TRIM24 has been shown to act as both a 
transcriptional co-activator and co-repressor. Targeted cancer gene expression analysis 
(nCounter) of TRIM24 over-expressing iHMECs revealed an up-regulation of genes 
significantly represented among citrate cycle, MAPK, mTOR ErbB, insulin and cell cycle 
pathways, while HTG EdgeSeq Oncology biomarker analysis revealed that TRIM24 over-
expressing MCF10A cells display gene expression consistent with EMT [48, 71]. Though 
iHMECs and MCF10A cells are both immortalized non-malignant breast epithelial cells, 
there methods of immortalization differ and may be the cause of different results of 
TRIM24 over-expression. iHMECS were immortalized by two rounds of benzopyrene 
treatment, allowing the cells to bypass stress-associated stasis[72]. MCF10As are 
spontaneously immortalized cells isolated from a patient presenting with non-
malignant fibrocystic disease of the breast[73]. While these studies have determined 
gene expression changes due to TRIM24 over-expression using analyses with targeted 
probe sets, no unbiased transcriptome profiling have been reported. With the goal of 
uncovering TRIM24’s full transcriptional regulatory network, in the context of breast 
cancer, we performed deep sequencing of RNA (RNA-seq) obtained from tumors and 
control, un-diseased mammary glands. Total RNA was isolated from three individual 
tumors along with one freshly isolated mammary gland by the size selection glass fiber 
filter-based mirVana[74]  and sequenced. RNA-sequencing data were analyzed using 
two independent algorithms, edgeR and DeSeq to determine differentially expressed 
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genes (DEGs) upon TRIM24 over-expression. edgeR analysis revealed a total of 1092 
significantly DEGs, 685 upregulated and 407 downregulated, while DeSeq discovered 
698 total significant DEGs, 407 upregulated, 291 downregulated. The two analyses 
shared 635 DEGs, 400 activated and 235 repressed by the over-expression of TRIM24.  
Functional annotation analysis was performed using the Gene Set Enrichment Analysis 
(GSEA) software.  According to this analysis, the top 5 upregulated hallmark gene sets 
were EMT, allograft rejection, complement, inflammatory response, and up-regulation 
of KRAS signaling. Of the downregulated genes, the top 5 significantly altered hallmark 
gene sets are TNF signaling via NF-B, Interferonresponse, interferonresponse, 
KRAS signaling down-regulation and early estrogen response (Figure 28). These data 
corroborate our histological data that TRIM24 over-expression is driving an EMT-like 
phenotype in the mammary gland and reveal additional pathway alterations that may 
be regulated by TRIM24, contributing to the tumorigenic phenotype. These changes 
were confirmed by quantitative PCR from multiple Cre (control) and Trim24COE tumors 
and mammary glands (Figure 29).  
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 Taken together, these data implicate TRIM24 as a potent proto-oncogene with 
the ability to regulated transcriptional changes that lead to the development of breast 
cancer in vivo.  We have demonstrated that Trim24-driven tumors arise beginning at 8 
months and mice have an average tumor free survival of 410 days, depletion of Trp53 
sis not affect the initiation time, but reduced the tumor free survival lime significantly, 
to 330 days. The breast tumor spectrum was heterogeneous with an over 
representation of carcinosarcomas. Tumors identified as carcinosarcomas stained 
positively for markers of EMT – loss of e-cadherin, gain of vimentin, positivity for both 
basal (K14) and luminal (K8) cytokeratins. Genome wide transcriptome analysis of these 
tumors revealed a significant up-regulation in EMT-related genes. I propose that this 
model is a potentially useful tool for modeling MpBC.   
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Figure 28 | RNA-sequencing results summary A) Venn diagrams showing overlap of 
differentially expressed genes as determined by EdgeR and DeSeq algorithms B) Hallmark 
analysis of differentially expressed genes. 
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Figure 29 | RNA-sequencing validation in tumors. Trim24COE tumors display high 
expression of EMT related transcripts, Twist, FN1, and Zeb1. 
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Chapter 5: Trim24COE tumor-derived cell lines as an in vitro model of 
MBC 
5.1 Introduction 
In order to perform genome-wide analysis of TRIM24 binding as well as other 
mechanistic studies, cell lines were derived from the mouse mammary gland tumors 
from TRIM24COE mice (ex vivo). Derivation of tumor cell lines as well as primary 
mammary epithelial cells is a well-established and accepted method for increasing the 
number of cells available for assays requiring a significant amount of material.  Many 
genome wide studies are performed in traditional established human cancer-derived 
cell lines. The usefulness of these approaches is reproducibility and the opportunity for 
the scientific community to share, learn from, compare and repeat the data.  
 
5.2 TRIM24-driven Tumor Cell Line Establishment Because we are interested in the 
function of TRIM24, specifically in the epithelial cells, mammary gland cultures were 
enriched for epithelial-like cells by differential centrifugation and plating.  Genotyping 
by PCR was also performed on these cells to ensure that they maintained genotype. 
TRIM24 over-expression was confirmed by both PCR and immunoblotting. Trim24 
transcript levels were approximately 3-fold higher than that of TRIM24-driven tumor-
derived cell lines (p=0.006) and TRIM24 protein is stabilized in Trim24COE tumor-
derived cell lines, whereas TRIM24 in CreTg/0 lines is undetectable(Figure).  
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Figure 30 | Confirmation of TRIM24 over-expression in tumor-derived cell lines A) RT-
qPCR analysis reveal that TRIM24 expression is 3-fold higher in over-expressing tumor-
derived cell line p=0.00627. B) Immunoblotting of endogenous and exogenous Flag-
TRIM24 protein levels. CreTg/0 cell line was derived from CreTg/0 mouse #823, 
Trim24COE cell line was derived from Trim24COE mouse #64. 
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While Trim24’s transcriptional coregulatory function takes place on the chromatin, the 
cellular compartment of its E3-ubiquitin ligase activity is yet to be determined, however 
TRIM24 expression has been observed in patients in both the nucleus and the 
cytoplasm [32]. Studies focused on delineating the cellular compartment-specific 
functions of TRIM24 are currently underway.  To assess the localization of TRIM24 in 
our TRIM24-driven tumor derived cell lines, we performed cellular fractionation. 
Interestingly, we identified that there are two independently migrating forms of 
TRIM24 that exist within our cell lines, the full length and truncated TRIM24, which run 
at approximately 150kDa and 60kDa, respectively, on an SDS-Page gel (Figure 31). 
Immunoblotting for Flag uncovered that the 60kDa fragment is from the carboxy-
terminus of the protein, as the 3X flag epitope was added to the C-terminus of mTrim24 
cDNA when the transgene was constructed.  Moreover, we Identified that while full 
length Flag-TRIM24 is almost exclusively bound to the chromatin, the 60kDa fragment 
is mostly cytoplasmic. Moreover, we have observed in a number of human cancer-
derived cell lines that express high levels of TRIM24 that this cleaved fragment is 
present (unpublished data). In MCF7 cells, this cleaved fragment is located in the 
cytoplasm, however the localization of those fragments in other cell lines has yet to be 
determined.  
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I created repository of 20 unique cell lines, 3 cell lines – CreTg/o #823, TRIM24COE #64, 
and TRIM24COE #897 -  were primarily used for the remainder of this study, except 
where noted. CreTg/o #823 was derived from a 13-month-old control mouse, which 
upon gross examination at the time of cell line derivation did not have a malignancy in 
the mammary gland. However, upon pathological scoring it was noted that she had 
areas of pre-malignancy in her mammary glands. This is a significant caveat which we 
are cognizant of when interpreting our data. However, it is encouraging that this animal 
and subsequent tumor derivations, does not express high levels of TRIM24, serving as 
a good control for cells transformed in the absence of TRIM24 over-expression. 
TRIM24COE lines 64 and 897 were derived from TRIM24COE mice whose histological 
scoring was carcinosarcoma and spindle cell carcinosarcoma, respectively. Prior to 
isolation of cell line 897, we determined the karyotype of lines 823 and 64. 
Interestingly, both cell lines were shown to have undergone significant genomic 
instability as evidenced by aneuploidy and the presence of multiple mutated 
chromosomes (Figure 32).  
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Figure 31 | Cellular Localization of TRIM24 in tumor derived cell lines. TRIM24 is 
localized to the chromatin in both Trp53+/- and Trp53+/-;Trim24COE tumor-derived 
cell lines. Right panel shows location of exogenous TRIM24 at both the chromatin and 
a cleaved fragment in the cytoplasm. 
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Figure 32 | Representative Karyotypes of mammary tumor-derived cell lines. There is  
evidence of genomic instability and a number of mutated chromosomes.  
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5.3 Trim24COE cells lines display increased proliferative capacity 
Acquisition of the ability to proliferate unchecked is one of Hanahan and Weinberg’s 
“Hallmarks of Cancer”[75], therefore proliferative potential is a respected initial 
measure of tumorigenic potential of cell lines. In order to confirm that the cells 
maintained their tumorigenic potential, we compared proliferation rates of 
TRIM24COE tumor-derived cell lines to CreTg/o. Compared to controls cells, both 
TRIM24-driven tumor derived cell lines proliferated at a significantly greater rate than 
that of the CreTg/o control cells (Figure). In colony formation assays, which assays cells’ 
ability to survive when plated at limited density as a method for determining 
transformative capacity, we observed that TRIM24COE cell lines had a much greater 
capacity to form colonies than that of the CreTg/o cell lines (Figure). In fact, CreTg/o 
cells were unable to survive in the colony formation assay.  TRIM24COE  lines #64 and 
#897 maintained the capacity to form robust colonies within 10 days when plating as 
few as 250 cells in a single well of a 6-well plate. Taken together, these data suggest 
that TRIM24COE  tumor-derived cell lines maintain their tumorigenic potential and 
possess a level  of transformation far greater than that of CreTg/o 823.   
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5.4 Assaying the altered transcriptome of TRIM24COE cell lines 
In order to determine how well the cell lines maintained their TRIM24-driven gene 
expression, we performed RNA-sequencing in the TRIM24COE tumor-derived cell lines 
to match the tumors that were sequenced. Significantly, we found there was no 
significantly DEGs between tumors and their matched cell lines. This increases our 
confidence in using these cell lines to test hypotheses derived from the mouse model. 
Upon analysis, we identified 678 genes that were differentially expressed between Cre 
control and TRIM24COE, 555 of which were shared with the DEGs between Cre breast 
epithelial cells and TRIM24COE tumors of which 283 were down regulated and 270 
were upregulated. The top downregulated pathways were interferon gamma and alpha 
responses, estrogen early and late response, MTORC1 signaling, p53 pathway, and Myc 
targets, while the most significantly upregulated pathways are epithelial mesenchymal 
transition, G2M checkpoint, E2F target, Mitotic spindle, and apoptosis.  
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The unbiased identification of EMT gene upregulation in our cell lines is intriguing as 
we observed that the cells lines had various morphological characteristics in colony 
formation assays (Figure 33). Some cells with epithelial characteristic, others more 
mesenchymal in appearance. Based on the process by which the tumor cells were 
isolated, the starting population of cells was enriched for epithelial cells and should 
have had very few, if any mesenchymal cells. However, this phenotype was one that 
we observed often, especially when growing cells from limiting cultures. Based on this 
observation, in conjunction with the pathological classification of our tumors as 
carcinosarcoma, and our RNA-sequencing data, we determined the expression of EMT 
markers in our cell lines. Quantitative PCR results show significant increases in levels of 
Twist1, FN1, Zeb1, and Vimentin. Strikingly, TRIM24COE cell lines lost all measurable 
expression of E-cadherin protein, while gaining the expression of Vimentin and Snai1 
(Figure 34). Taken together, these data confirm that our tumor-derived cell lines indeed 
represent cells which have undergone an epithelial-mesenchymal transition. 
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Figure 33 | TRIM24COE Tumor-derived cells maintain tumorigenic properties. A) 
Proliferation assays over 10 days in a 24 well plate starting with 1000 cells. TRIM24COE 
cells grow significantly faster than CreTg/o (p,0.0005). B) Crystal violet stained colony 
formation assay over 10 days starting with 500 cells in a 6 well plate. Average colony 
formation for CreTg/o is 4, TRIM24coe, 45 p=0.001. 
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Figure 34 | RNA-seq Analysis. A) Venn diagram of differentially expressed genes in 
tumor and corresponding cell lines. B) Pathway analysis performed using the GSEA mSig 
database.  
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Figure 35 | TRIM24COE Cell Lines are heterogeneous. A) Crystal violet stained colonies 
of TRIM24COE cell line #64 with varying morphologies. B) High magnification images of 
crystal violet stained cells from all genotypes showing representative morphologies.  
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Figure 36 | RNA-seq Validation. qPCR validation of EMT markers in tumor tissues. Vim 
p<0.000001, Met p<0.00002. 
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5.5 Determining the genome wide chromatin enrichment profile of TRIM24 in mammary 
tumors Chromatin Immunoprecipitation followed by deep sequencing of DNA (ChIP-
Seq) was performed to determine genome-wide enrichment of TRIM24 on chromatin 
in tumor cell lines. When compared to CreTg/o cell lines, we found enrichment of 9338 
peaks of TRIM24 on chromatin in TRIM24COE cell lines. TRIM24 bound peaks were 
enriched mostly on gene promoters however the binding of TRIM24 was distributed as 
follows to other genetic elements: 36.4% promoter, 19.2% introns, 3.4% exons, 8.4% 
upstream, 16.1 % downstream, 13.4% intergenic, 3.1% transcription end site. Genes 
with a TRIM24 binding peak within 10kb of their TSS were called as TRIM24 bound 
genes. TRIM24 bound genes were enriched in pathways including TNF signaling 
through Nf-kB, G2M checkpoint, Myc Targets, UV Response, Hypoxia, E2F targets, 
Mitotic Spindle, unfolded protein response, TGF-Beta signaling, and p53 pathway.  
Comparative genomic analyses of TRIM24 bound genes (ChIP-Seq) with DEGs (RNA-
seq) revealed direct gene targets of TRIM24 of which 40 are activated and 62 are 
repressed by TRIM24. Genes directly activated by TRIM24 are enriched in the EMT 
pathway, E2f Targets, G2m Checkpoint, and late estrogen response. Genes directly 
repressed by TRIM24 are enriched in early estrogen response, heme metabolism, UV 
response, and late estrogen response and glycolysis (also: MTORC1 signaling, ROS 
Pathway, hypoxia, inflammatory response, p35 pathway).  Taken together, these 
genomic profiling data from both in vivo and ex vivo models lead us to conclude that 
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transcription co-regulator TRIM24 drive mammary tumorigenesis by promoting an EMT 
phenotype, altering general transcription, the cell cycle and metabolism.  
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Chapter 6: Discussion and future directions 
The results of this work support the hypothesis that TRIM24 over-expression is 
sufficient to drive tumorigenesis in the mammary gland.  Since the Barton lab’s discovery of 
TRIM24 stabilization in human breast cancers [32] a number of studies have been published 
corroborating our findings in breast cancer and other tumor types. While many of these 
reports are correlative, our lab has previously demonstrated a causative role for TRIM24 over-
expression driving transformation in vitro through reprogramming the metabolic state of 
iHMECs[48]. The goal of the present work is to elucidate the ability of TRIM24 to drive 
tumorigenesis in vivo.  By achieving tumorigenesis though over-expression of TRIM24 in the 
absence of any other genetic alterations, our model implicates TRIM24 as a driver of cancer in 
the mouse mammary gland. Comparing the transcriptomes of TRIM24-driven tumors with 
normal, undamaged mammary epithelia, we have uncovered the transcriptional profile of 
genes regulated by TRIM24.  Trim24 over-expressing tumors and tumor-derived cell lines 
display a significant increase in genes involved in a number of pathways, most significantly, the 
epithelial-mesenchymal transition (EMT).  Moreover, the Trim24 mouse model phenotype is 
resonant of what is seen in human MpBC patients. I believe that this mouse model can serve 
as a suitable model in the breast cancer field to uncover the mechanisms of MpBC and to test 
prospective therapies.  
6.1 TRIM24 as a co-regulator of hormone receptor signaling  
Mammary gland development is a complex process elegantly orchestrated by a sequential 
cascade of secreted hormones and their cognate receptors. Each stage of mammary gland 
development is uniquely controlled by a specific hormone receptor protein which controls the 
elongation (ER), branching (PR), and differentiation (PrlR) of the epithelial cells of the 
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mammary gland. Numerous studies have indicated that deletion of any single hormone 
receptor gene  has a stage-specific effect on the developmental process of the mammary gland 
network (reviewed in [76]).  While Trim24-/- mammary glands display delayed development 
through 6 weeks of age, mammary gland development there after appears to continue 
normally. Intriguingly, it has been observed but not reported that breeding through the 
TRIM24-/- female mouse is a challenge due to a seeming “failure to thrive phenotype” of pups 
born to mother who have previously birthed and nursed more than four litters.  This 
phenotype was rescued by fostering the pups onto wild type mothers. Though this line of study 
was beyond the scope of this project, it is an interesting observation as TRIM33, a structurally 
similar family member and protein interacting partner of TRIM24, has been shown to play an 
essential role in the proper differentiation of the mammary epithelial alveoli and regulate 
expression of milk genes in the mammary gland[77]. Moreover, genome wide chromatin 
occupancy studies in the mouse liver revealed TRIM24 binding at the lactoferrin (LTF) proximal 
promoter. It is feasible that TRIM24 and TRIM33 work in concert to bring about the full 
function of the mammary gland from development through alveolar differentiation, lactation, 
and involution.  
The complexity of molecules involved in mammary gland development is made more 
complex by the compartmentalization of signal transduction. Progesterone Receptor can play 
two distinct roles depending on its location: epithelial PR is required for alveolar 
differentiation, while stromal PR is essential for ductal elongation[78]. Taking into account that 
our TRIM24-/- mouse is a germline deletion, we are not able to delineate these differences. It 
is, however plausible that TRIM24 may play a role in disseminating the stromal-PR signal during 
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ductal elongation. Additionally, while only approximately 30% of the epithelial cells in the 
mammary gland express ER and PR, it is the ER-/PR- cells that actually proliferate [76]. 
Identifying which cells TRIM24 is required in to promote proliferation would be of value to 
determine if TRIM24 propagates the autocrine or paracrine signals in the mammary gland. 
Furthermore, confining TRIM24 deletion to the epithelial or stromal cells of the mammary 
gland could reveal interesting biology regarding its role in regulating transcription of the ligand 
bound hormone receptors across different cell types. The transcriptional co-regulation of 
TRIM24 and PR is of particular interested as TRIM24 is found bound to PGR in human MCF7 
cells and is upregulated in our tumor model by RNA and protein. While PR-responsive 
transcription through RANKL promotes the development of side branches, through Wnt4[79], 
both RANKL (Tnfsf11) and Wnt4 are upregulated in Trim24COE tumors. Furthermore, Rankl-/- 
mice have a severe lactation defect[8, 80] suggesting a potential role for TRIM 24 as a mediator 
of PR target gene expression during both development and tumorigenesis. 
Long-term exposure to hormones is cited as a cause development of breast cancers[81]. 
As many of our mice develop tumors at an age that is considered to be the onset of 
reproductive senescence it is intriguing to think that TRIM24’s role as a nuclear receptor 
interacting protein may be playing a role at this specific time. More intriguingly is the finding 
that in a cohort of C57/B6 mice, 70% of the female mice actually entered a state of constant 
estrus while the remaining mice lost hormone secretion completely[82]. While it is not clear if 
perpetual estrus after 8 months of age is true in all mouse backgrounds, it may be of interest 
to monitor the estrous cycle in the Trim24COE  cohort  as our model has a considerably long 
latency. These findings may offer a clue as to why the initiation time and penetrance of our 
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tumor phenotype is so long. The Barton lab has transgenic mouse embryos which possess the 
TRIM24 over-expression construct with a LxxLL motif mutated version of TRIM24. This mouse 
model or CRISPR targeting of the LxxLL motif in the present mouse model would reveal the 
hormone interaction dependence of the phenotype. Alternatively, removing the hormonal 
component through overiectomy as an adult (young overiectomized mice do not develop 
mammary glands), or increasing the hormonal load earlier in life through pregnancy could give 
insight into the role that hormone signaling has on the TRIM24-driven phenotype. Of note, the 
median tumor free survival age of TRIM24COE mice used to breed was 328 days, less than that 
of virgin mice, though not significantly. While a great deal of nuclear receptor signaling in the 
mammary gland is known, including that ER has nearly 500 target genes with over 4,000 
unique binding sites, termed “estrogen receptor elements (EREs)[83] the epigenetic landscape 
in the mouse mammary gland is still not well understood. One study began to address this 
question by elucidating the differences in chromatin marks at the Casein milk gene locus 
between virgin and lactating murine mammary glands. Intriguingly a significant increase of 
acetylation was confirmed on  Histone 3 (no specific residue)[84]. As TRIM24 is a reader of 
acetylated lysine 23 on histone 3, it is possible that a loss of TRIM24 in the lactating mammary 
gland can cause a defect in the successful rearrangement of the chromatin structure, thereby 
causing a defect in milk production. Such a finding would shed light on the failure to thrive 
observation in TRIM24-/- lactating females.  
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6.2 Regulating TRIM24 
While we have begun to uncover the role of TRIM24 in the mammary gland as a co-
activator, we also find that many different post translation modifications (PTMs) of TIRM24 
that are changed as a result of certain stimuli, many of which remain to be identified. Each of 
these post translational modifications (PTMs), or a combination of PTMs, may alter the 
assembly of proteins interacting with TRIM24, the sub-cellular compartment of localization 
and ultimately effects on nuclear signaling or other functions. One well studied transcriptional 
co-regulator in the mammary gland which is effected by various PTMs, including ubiquitination 
and phosphorylation is SRC-3 [85-87]. SCR-3 is over-expressed in breast cancers and is 
generally accepted as an oncogenic protein, one that undergoes transcription-mediated 
ubiquitination and degradation.  A model has been put forth that during development 
expression levels, SRC-3 acts as a limiting factor of ER-regulated transcription. The model 
suggests that ER is bound at its target genes, only promoting robust transcription upon the 
interaction with the co-regulator SRC-3. When SRC-3 is expressed at the developmentally 
appropriate level of transcriptional co-regulator SRC-3 are increased, competition by 
chromatin-bound ER for SRC-3 binding is decreased and transcription can occur at all 
interacting sites, thereby promoting proliferation [88]. Additionally, SCR-3 has been correlated 
with speckle type POZ protein (SPOP), a CUL3-ubiquitin ligase also associated with TRIM24 in 
castrate resistant prostate cancer (CRPC)[89]. In MCF7 cells, SPOP promotes SRC-3 turnover in 
a phosphorylation-dependent manner[90]. Moreover, it has been shown in prostate cancer 
that mutations in SPOP promote stabilization of TRIM24[47], suggesting that SPOP is a 
regulator of TRIM24 levels. While the Trim24 over-expressing mouse model develops 
mammary tumors, the Trim24-/- (both germline and liver-specific) mouse develops liver 
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tumors, suggesting the importance of optimal levels of TRIM24 in order to maintain 
homeostasis. We have very little understanding of how TRIM24 is regulated. Two recently 
published studies suggest possible mechanisms for regulating TRIM24. Post-transcriptionally, 
the Xiong lab has shown that TRIM24 is a direct target of miR-511 in gastric cancers, where 
they’ve also demonstrated that TRIM24 promotes tumor aggression by activating the Wnt/-
catenin pathway [91, 92].  At the protein level, the Brown lab has demonstrated that TRIM24 
is a target for SPOP-mediated ubiquitination and proteasomal degradation. Little is known 
about miR-511 in breast cancer, however SPOP loss of heterozygosity is amongst the highest 
is breast cancer. More intriguingly, PR is a direct ubiquitin substrate of SPOP[93]. A mutant 
SPOP over-expressing mouse model recently published, demonstrated the ability of SPOP to 
drive tumorigenesis in the prostate through activation of PI3K/mTOR pathways and androgen 
receptor activation[94]. It is plausible that TRIM24 may be the target of SPOP that is driving 
this phenotype as we have seen in our model that over-expression of TRIM24 can drive mTOR 
and PI3K pathway and the Brown lab has shown that TRIM24 co-activates AR signaling. 
Determining the ability of SPOP to regulate TRIM24 in breast cancer is an intriguing question 
as we are largely unaware of any other regulatory mechanisms for TRIM24. Studies are 
underway in the lab to identify regulator of TRIM24 by employing a CRISPR screen. 
 
6.3 Modeling the Progression of Breast Cancer in vivo 
The breast can acquire over 30 abnormalities, some of which are benign, while others are 
deadly. The most common form of proliferative breast disease is epithelial hyperplasia 
resulting from an increased number of epithelial cells lining the lumen. There are various 
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gradations of this disease, the worst of which is atypical hyperplasia. Atypical hyperplasias are 
more than mere increases in the layers of luminal epithelium, but actually mimic the 
histological features of low-grade breast tumors. These lesions are found in 31% of biopsies 
performed due to the presence of a microcalcification and can be indicative of future breast 
disease [95, 96]. In a 2014 study of 698 women with atypical hyperplasia conducted by the 
Mayo Clinic, 30% of the women developed breast cancer within 25 years [97]. Of the women 
in this study that developed breast cancer, 79% of them developed invasive ductal carcinomas 
(IDC), many of which were of advanced grade.  While a significant number of animals in out 
Trim24COE cohort developed atypical hyperplasia, and those with tumors had atypical 
hyperplasia of the uninvolved mammary glands, we did not determine if the atypical 
hyperplasia developed in mice at 2 months of age regressed, persisted, or developed into 
ductal carcinoma in situ or invasive ductal carcinoma. WE also did not determine whether 
Trim24COE mice, which did not develop tumors, had lower expression of TRIM24. A study in 
which various levels of TRIM24 over-expression are assessed for their downstream effects at 
the level of mammary hyperplasia, tumor development and other parameters over a time 
course is worthwhile for the future. We have seen in clinical data and commercial tumor arrays 
that TRIM24 expression levels vary and that increases of expression are correlated with poor 
prognosis and reduced patient survival [32, 48]. A mouse model which allows modulation of 
the levels of trimm24, will help delineate cause-and-effect between specific levels of TRIM24 
and outcomes.  
These questions are critical to answer in understanding the role of TRIM24 in the 
progression of disease. To assess this, an approach which allows tracking the growth of TRIM24 
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over-expressing cells over time would be a useful tool. The lab is currently making use of the 
Td-Tomato mouse which will allow visualization mammary gland cells that express Cre through 
live cell imaging. This approach is useful as it offers the ability to fluorescently mark cells and 
follow them throughout their development without ending the life of the mouse. This is also 
crucial in helping determine why there is heterogeneity in the expression of Flag-TRIM24 in 
the mouse tumors. Our model is consistent in showing negativity for ER and Her2. TRIM24 
association with ER- and PR- cancers has detailed in a recent report [98]. As our model is similar 
to MpBC, a subtype of TNBC, TRIM24 could be a bona fide molecular marker of MpBC. A 
comprehensive study of MPCs and their immunohistochemical staining revealed additional 
markers that can be applied to diagnosis. 80% of MBC (172 total) were positive for broad 
cytokeratins, CK8/18, 7, 19 were positive in 30-60% (luminal), basal CK (5/6, 14, 17) positive in 
70%, p63 and SMA myoepithelial markers were present [25]. MpBCs show EMT, cancer stem 
cell signatures, PI3K pathway activation loss of PTEN[99]. We have demonstrated that our 
mouse model expressed classical EMT proteins and have alterations in PI3K pathway. Some of 
the mice in our cohort retain e-cadherin expression though they also have high levels of 
vimentin expression. Interestingly, an immunohistochemical analysis of 13 MpBCs in which IHC 
we performed for Vimentin and E-cadherin amongst other markers, found that some tumors 
expressed both makers in the same tumors, though in different components (epithelial or 
mesenchymal) of the tumor [100], in biphasic tumors. Interestingly, this mimics what we’ve 
found in our model, indicating that this could be a good representation of these biphasic 
tumors. A recent profiling of 297 MpBCs revealed that in addition to the known molecular 
alterations, expression of the programed death ligand-1 (PD-L1) is increased as compared to 
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TNBCs[70]. Intriguingly our RNA-sequencing analysis uncovered a significant 3.8-fold increase 
in Pdcd1lg1/Cd274 (aliases for) the gene encoding PD-L1 in Trim24COE tumors compared to 
normal mammary gland. To our knowledge our model is the only mouse model of metaplastic 
breast cancer that represents the dual cell phenotype. Two recently described models of 
MpBC are more characteristic of spindle cell metaplastic carcinomas.  
One model in which Ccn6, the gene encoding a secreted matricellular protein, was deleted 
in the mouse mammary gland, driven by the MMTV-Cre promoter. They found a negative 
correlation of CCN6 with human spindle cell metaplastic carcinoma and propose that their 
mouse model, which develops spindle cell carcinoma, recapitulates the human disease [101]. 
Strikingly, a number of deregulated genes from their study, including Fzd3, Foxa1, Tgfb1i1, 
Krt19, Stat5b, and Abcd3, which they found to also be deregulated in human MpBCs are 
deregulated in our mouse model as well, suggesting that CCn6/WISP3 and TRIM24 may be in 
the same pathway or that they lead to the activation of the same or converging pathways. In 
a novel mouse model in which the tyrosine kinase receptor, MET is overexpressed in a K14-
Brca1-/-;Trp53+/- background, half of their mouse cohort develop carcinomas while the 
remainder develop spindle cell carcinosarcoma, whereas those mice that did not over-express 
Met only developed carcinomas. Strikingly, Met was found to be highly over expressed in our 
mouse tumors by RNA-sequencing and confirmed by q-RTPCR, suggesting that TRIM24-
mediated Met over-expression could be a key promoting factor in MpBCs. Furthermore, both 
studies demonstrated significant decrease of expression of claudins 3 and 4 (Cldn3 and Cldn4) 
in their carcinosarcomas. RNA-sequencing in Trim24COE also revealed decreased expression of 
Cldn3 and  Cldn4, as well as Cldn1, Cldn6, Cldn7 and Cldn10. Intriguingly, claudin-low breast 
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cancers have recently been discovered to have EMT-related gene expression patterns [67]. 
While we did not assess the claudin levels of all of the tumors in our cohort, this would be 
beneficial to further implicate TRIM24 as a driver of this subtype of breast cancer.  
The World Health Organization has categorized MpBCs into 10 categories based on their 
cellular features. Those categories are as follows: metaplastic carcinoma of no special type, 
low-grade adenosquamous carcinoma, fibromatosis-like metaplastic carcinoma, squamous 
cell carcinoma, spindle cell carcinoma, metaplastic carcinoma with mesenchymal 
differentiation, chondroid differentiation, osseous differentiation, mixed metaplastic 
carcinoma, and myoepithelial carcinoma[19, 29]. It is of particular interest that both of the 
above-mentioned mouse models appear to only develop spindle cell carcinomas.  These 
tumors appear to be completely comprised of spindle cells and the epithelial protein 
expression must be confirmed by immunohistochemistry.  In contrast the Trim24COE mouse 
model appears to has the ability to produce not only spindle cell carcinomas, but also mixed 
metaplastic carcinomas with clear epithelial and sarcoma elements. Future exploration into 
the molecular (genetic, transcriptional, and proteomic) differences between these different 
types of tumors in our mouse model could be useful in guiding what potential therapeutics 
would be best tested in our mouse model as well as guiding how TRIM24 over-expression is 
employed to inform clinicians on classification or therapy options. 
 
 
6.4 Modeling Metaplastic Carcinoma in vitro  
While in vivo experiments with therapeutics are ideal for testing the potential of a drug to 
effectively inhibit tumor growth in the clinic, cell lines offer the ability to gain preliminary 
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insights into the efficacy of the drug as well as address some mechanistic questions. A small 
molecule targeting the TRIM24 bromodomain was developed by the MD Anderson Institute of 
Applied Cancer Science [102]. This molecule, IACS9571 has the ability to disrupt TRIM24 
chromatin binding, however little is known about the functional efficacy of this molecule. As 
preliminary data employing siRNA knockdown of Trim24 in the Trim24COE tumor-derived cells 
indicated that these cells are dependent on TRIM24 to maintain sustained proliferative 
potential, drugs that target TRIM24 are good candidates for therapy in such tumors.  
Preliminary studies in the Trim24COE tumor-derived cell lines indicate that inhibition of 
TRIM24 chromatin interaction can reduce proliferation while having no effect on control cells. 
More recent experiments have been performed with a bifunctional TRIM24 degrader which 
employs IACS9571 to bind TRIM24 and while simultaneously binding Cereblon, an E3-ubiquitin 
ligase, bringing the two proteins into close proximity to achieve target gene degradation.  
These experiments demonstrate that TRIM24 is successfully degraded in the presence of this 
compound. Studies in the lab are ongoing to determine the consequence on cell proliferation 
and survival in the presence of this inhibitor. Future studies to assess the ability of this 
molecule to reduce tumor burden in vivo would be pertinent to move forward with promoting 
this molecule as a potential therapeutic in the clinic. Additionally, IACS9571 can be used to test 
chromatin binding-independent functions of TRIM24 as well as alterations in transcription 
after treatment.  
 Trim24COE tumor ChIP-sequencing identified potential TRIM24 binding sites 
throughout the mouse genome. Of note is the potential binding of TRIM24 at the Trp53 
promoter. The genetic interaction of TRI24 and p53 is still a question of great interest to the 
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Barton lab. Based on data from MCF7 cells, TRIM24 has no effect on the transcription of Tp53.  
However, when TRIM24 is over-expressed in both mouse and human cell lines, we do find a 
significant decrease in p53 gene expression suggesting that either TRIM24 or a downstream 
target of TRIM24 can directly regulated the transcription of this tumor-suppressor. ChIP-
sequencing data from our mouse cell lines located a potential TRIM24 binding site in the 
mouse Trp53 promoter. This finding in intriguing as it adds complexity to the TRIM24 auto-
regulator feedback loop. We have published that TRIM24 is a negative regulator of p53 by 
post-translational ubiquitination and that p53 directly regulates TRIM24  expression in 
response to DNA damage[37, 38]. The addition of transcriptional regulation of Trp53 to  
TRIM24’s repertoire would be an interesting finding, adding to the complexity of p53 
regulatory loop.  
This study uncovered previously unknown target of TRIM24 association with 
chromatin, but the specific DNA-binding proteins or other factors, which TRIM24 binds at 
these target genes, remains to be identified. The literature indicates that TRIM24 can interact 
with nuclear receptors, however, as our tumors are negative for ER by immunohistochemistry, 
it is unreasonable to think that ER is the binding partner in this case.  Because of the 
stabilization of PR in these tumors[103], I hypothesize that PR is one of the nuclear receptor 
with which TRIM24 is interacting in these tumor tissues. In order to assess this, we should 
perform sequential ChIPs at known PR target genes that are present in our TRIM24 ChIP-
sequencing data. A publication of genome-wide binding of PR in human breast cancer cells 
revealed over 30,000 PR binding sites[104]. Overlapping these binding sites with those 
generated from our ChIP-seq data uncovered 131 common genes. Intriguingly, Twist1 a 
 105 
regulator of EMT is among the genes found to have both PR and TRIM24 binding sites near the 
promoter. As Twist is highly upregulated in our tumors and tumor cell lines by both RNA-
sequencing, q-PCR and immunoblotting, and is a key transcription factor in EMT, this gene is 
an ideal first candidate.   
Clinical evidence demonstrates that a population of cells in some breast cancers are 
refractory to treatment. This subpopulation of cells has the ability to proliferate at high rates, 
self–renew, and give rise to heterogeneous tumors are termed “cancer stem cells” or “tumor 
initiating cells” [105].  Metaplastic Breast Cancers are known to show enrichment for these 
tumor-initiating cells, as measured by presence of the cell surface markers ALDH-1 and CD44 
and low expression of CD24[106]. Additional markers used to isolate breast cancer stem cells 
are high CD133, CD49f, or CD61[107]. Preliminary single cell analysis of tumor-derived cells 
indicates that TRIM24 over-expressing cells express stem-like markers. This finding is intriguing 
as is mimics the MpBC clinical phenotype, further suggesting that our model is a close 
recapitulation of the human phenotype, even when grown in culture.  These cell lines could 
be useful for testing the efficacy of single therapies or combination therapies to significantly 
inhibit the survival of this subpopulation of cells.  
Finally, as we have uncovered a unique phenotype in our mouse model, our findings 
have also led to many additional questions about TRIM24’s function, regulation, and 
mechanism of action in both developing and diseased mammary glands. Furthermore, the 
implication of TRIM24 as a driver of EMT and the requirement that cells have on TRIM24 
should encourage the establishment of TRIM24 as a molecular marker in MpBC patients to 
guide therapies that target Bromodomain proteins, including TRIM24[102]. Continued 
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investigation into the clinically relevant functions of TRIM24 in the mammary gland could shed 
light on the mechanisms of tumor development as a result of aberrant TRIM24 expression ion 
the mammary gland and lead to improved characterization and therapeutic opportunities for 
patients.  
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Chapter 7: Conclusions 
  
 We have shown that TRIM24 is a potent proto-oncogene in the mammary gland. In 
the initial part of the study, I show that development of the mammary gland is delayed in the 
absence of Trim24. While these mouse mammary glands do ultimately recover to develop at 
the same rate as wild type mammary gland, we have observed that there are potential 
lactation defects. Deeper investigation into this phenotype is warranted in order to 
understand the normal developmental mechanisms TRIM24 plays a role in regulating. 
 The main body of this work is built upon the characterization of a novel mouse model 
in which Trim24 is over-expressed in the mouse mammary gland. I show that mice expressing 
moderately increased levels of Trim24 have the propensity to develop a heterogeneous array 
of tumors. Furthermore, the depletion of a single copy of Trp53 significantly increases the 
penetrance of the phenotype, without affecting the time of initiation. Intriguingly, I have 
uncovered the capacity for Trim24 over-expression to give rise to a very rare breast cancer 
phenotype, carcinosarcoma or MpBC. This type of breast cancer is characterized by a lack of 
expression of the hormone receptors ER, PR, and ERBB2 while expressing markers of EMT. 
Our model recapitulates both of these molecular characteristics. To our knowledge, our 
mouse model is the first to develop the carcinosarcoma-type MpBC. Finally, I have developed 
a number of tumor-derived cell lines that maintain their tumorigenic potential and EMT 
signature. I’ve shown that these cell lines have lost expression of e-cadherin while gaining 
high expression of TWIST1, VIMENTIN, FN1. Deep sequencing of RNA shows a significant 
increase in EMT genes as well as misregulation of inflammatory, ER, mTORC, and p53 signaling 
pathways. Furthermore, ChIP-sequencing revealed that TRIM24 potentially directly regulates 
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these genes. Taken together, our model has established TRIM24 as an oncogene with the 
ability to drive an aggressive EMT phenotype. This model has the potential to be utilized as a 
tool to test the efficacies of TRIM24 targeted and combination therapies in the journey to 
improve outcomes for MpBC patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 109 
 
 
 
 
Appendix 1| Primers 
 
 
piggyback Cloning 
mTRIM24-FL-F CACCATGGAGGTGGCTGTGGAGAAG 
mTRIM24-3XFlag-R  TTACTTGTCATCGTCATCCTTGTAATCGATATCATGATCTTTATAATCACCG
TCATGGTCTTTGTAGTCCTTAAGCAGCTGGCGATCCTCGGTG 
Southern Probe Cloning 
mTrim24-SB-F  TCTAATCACCAAACTGATGGAAAAA 
mTrim24-SB-R  GATCTGTGTTGGGAACTTGGATAAC 
Genotyping 
P23 AATGAAGACTGGTGTGCTGTTTGT 
 
P24 TCGTCTGAGTCGTCACTGAACTTAC  
Cre1 GCGGTCTGGCAGTAAAAACTATC 
Cre2 GTGAAACAGCATTGCTGTCACTT  
P53 x6 AGCGTGGTGGTACCTTATGAGC 
  
P53 x7 GGATGGTGGTATACTCAGAGCC 
  
P53 Neo GCTATCAGGACATAGCGTTGGC 
  
qRT-PCR 
Twist1 F GCCGGAGACCTAGATGTCATTG 
 
Twist1 R CACGCCCTGATTCTTGTGAA 
 
FN1 F CCCAGACTTATGGTGGCAATT 
 
FN1 R AATTTCCGCCTCGAGTCTGA 
 
Zeb1 F GCCAGCAGTCATGATGAAAA 
 
Zeb1 R TATCACAATACGGGCAGGTG 
 
Trim24 F CGGCCGGTGGTCCTT 
 
Trim24 R CAAACTGGCATCGAATGAC 
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Zeb2 F GGAGGAAAAACGTGGTGAACTAT 
 
Zeb2 R GCAATGTGAAGCTTGTCCTCTT 
 
Snai1 F CTCTGAAGATGCACATCCGAA 
 
Snai1 R GGCTTCTCACCAGTGTGGGT 
 
Vimentin F CCAACCTTTTCTTCCCTGAA 
 
Vimentin R TTGAGTGGGTGTCAACCAGA 
 
TGFB F GGAGAGCCCTGGATACCAC   
TGFB R CAACCCAGGTCCTTCCTAAA 
PI3KR2 F CCCTTGGATGGATCTTCTGA 
PI3KR2 R AATGGCTTCCACCAGCTTC   
MET F CATTTTTACGGACCCAACCA 
MET R TGTCCGATACTCGTCACTGC    
CenpA F GACCCCAAGGAGGAGACC  
 
CenpA R TTCTGTCTTCTGCGCAGTGT  
 
CenpE R CCAGCACACAGTAACCCCTT   
CenpE F AGACCAGCTCAAGGACAACC 
FZD3 F CATCTGGGAGACAACATGGA 
FZD3 R GAATCAGGTCTGGACGACTC    
Dkk F CATCTCGGAGAAAGTCGAG   
Dkk R GGGGGCTCTTTTGCTTCTAC 
Wnt5b F 
GGGGAGAGACAGTGTGGG   
Wnt5b R AACATCTTCCAAAGCGGAGC 
Cyp1a F TTTGGGAGGAAGTGGAAGG 
 
Cyp1a R AGAATACGGTGACAGCCAGG 
 
Cyp24a1 F AACTGTACGCTGCTGTCACG 
Cyp24a1 R CTCTGTTGCACTTGGGGATT   
Jak3 F CTCATGCAGCTGTGCTGG  
 
Jak3 R CTGCAGCAGCTCCCTCTC 
 
Rarrers1 F GTGCACAATCAAACCAAACG 
Rarrers1 R GTGGACTATCCGGCCTAGA    
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Appendix 2: Antibodies 
 
Antibody Target Company Application 
TRIM24 TRIM24 Protein 
Technologies 
WB, IHC 
ER Estrogen Receptor 
Alpha 
Santa Cruz IHC 
PR Progesterone 
Receptor 
Protein 
Technologies 
IHC 
ERBB2 ERBB2 Santa Cruz IHC 
VIMENTIN VIMENTIN Abcam IHC 
E-CADHERIN E-CADHERIN Santa Cruz IHC 
FLAG M2 (FLAG) epitope Sigma IHC 
FLAG-HRP M2 (FLAG) epitope Sigma IHC 
K8 Keratin 8 Developmental 
Studies Hybridoma 
Bank 
IHC 
K14 Keratin 14 Covance  
Key: WB: western blot, IHC: Immunohistochemistry 
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Appendix 3: Necropsy results 
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Appendix 4: Tumor-Derived Cell Lines 
Cell Line Identifier Genotype Tissue Type 
173 CreTg/0 Mammary Epithelial Cells 
823 CreTg/0 Mammary Epithelial Cells 
2044 p53+/-CreTg/o Mammary Tumor 
628 p53+/-CreTg/o Mammary Tumor 
89 TRIM24COE Mammary Tumor 
567 TRIM24COE Mammary Tumor 
64M TRIM24COE Mammary Epithelial Cells 
64T TRIM24COE Mammary Tumor 
897 TRIM24COE Mammary Tumor 
2642 TRIM24COE Mammary Tumor 
561M p53+/-TRIM24COE Mammary Epithelial Cells 
561T p53+/-TRIM24COE Mammary Tumor 
500M p53+/-TRIM24COE Mammary Epithelial Cells 
500T p53+/-TRIM24COE Mammary Tumor 
2042T1 p53+/-TRIM24COE Mammary Tumor 
2042T2 p53+/-TRIM24COE Mammary Tumor 
2042T3 p53+/-TRIM24COE Mammary Tumor 
134 p53+/- Mammary Tumor 
135 p53+/-TRIM24COE Mammary Tumor 
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Appendix 5: Differentially expressed genes in Trim24COE tumor-derived cell lines compared to 
CreTg/o mammary epithelial cells  
303 p53+/-TRIM24COE Mammary Tumor 
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Appendix  6: Differentially expressed genes in Trim24COE tumor-derived cell lines compared to 
Trp53+/-;Trim24COE tumor-derived cell lines 
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Appendix 7: Differentially expressed genes in Trp53+/- tumor-derived cell lines compared to 
Trp53+/-;Trim24COE tumor derived cell lines 
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